<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hydromorphone for cancer pain - Li, Y - 2021 | Cochrane Library</title> <meta content="Hydromorphone for cancer pain - Li, Y - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011108.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hydromorphone for cancer pain - Li, Y - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011108.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011108.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Hydromorphone for cancer pain" name="citation_title"/> <meta content="Yan Li" name="citation_author"/> <meta content="The People's Hospital of Jizhou District, Tianjin" name="citation_author_institution"/> <meta content="Jun Ma" name="citation_author"/> <meta content="Beijing Anzhen Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="Guijun Lu" name="citation_author"/> <meta content="Beijing Tsinghua Changgung Hospital" name="citation_author_institution"/> <meta content="Zhi Dou" name="citation_author"/> <meta content="Xuanwu Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="Roger Knaggs" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Jun Xia" name="citation_author"/> <meta content="The Ingenuity Centre, The University of Nottingham" name="citation_author_institution"/> <meta content="Sai Zhao" name="citation_author"/> <meta content="The Ingenuity Centre, The University of Nottingham" name="citation_author_institution"/> <meta content="Sitong Dong" name="citation_author"/> <meta content="University of Nottingham" name="citation_author_institution"/> <meta content="Liqiang Yang" name="citation_author"/> <meta content="Xuanwu Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="yangliqiangxwpain@outlook.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD011108.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/08/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011108.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011108.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011108.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics, Opioid [adverse effects]; *Cancer Pain [drug therapy]; Hydromorphone [adverse effects]; Morphine [adverse effects]; *Neoplasms [complications]; Oxycodone" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011108.pub3&amp;doi=10.1002/14651858.CD011108.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011108\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011108\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","de","zh_HANT","ko","ms","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011108.pub3",title:"Hydromorphone for cancer pain",firstPublishedDate:"Aug 5, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011108.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011108.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011108.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011108.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011108.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011108.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011108.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011108.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011108.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011108.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4269 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011108.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0101"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-sec-0095"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/appendices#CD011108-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/table_n/CD011108StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/table_n/CD011108StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hydromorphone for cancer pain</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0004">Yan Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0005">Jun Ma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0006">Guijun Lu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0007">Zhi Dou</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0008">Roger Knaggs</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0009">Jun Xia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0010">Sai Zhao</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0011">Sitong Dong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information#CD011108-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Liqiang Yang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information/en#CD011108-sec-0116">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 August 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011108.pub3">https://doi.org/10.1002/14651858.CD011108.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011108-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011108-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011108-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011108-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011108-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011108-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011108-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011108-abs-0001" lang="en"> <section id="CD011108-sec-0001"> <h3 class="title" id="CD011108-sec-0001">Background</h3> <p>This is an update of the original Cochrane Review first published in Issue 10, 2016. For people with advanced cancer, the prevalence of pain can be as high as 90%. Cancer pain is a distressing symptom that tends to worsen as the disease progresses. Evidence suggests that opioid pharmacotherapy is the most effective of these therapies. Hydromorphone appears to be an alternative opioid analgesic which may help relieve these symptoms. </p> </section> <section id="CD011108-sec-0002"> <h3 class="title" id="CD011108-sec-0002">Objectives</h3> <p>To determine the analgesic efficacy of hydromorphone in relieving cancer pain, as well as the incidence and severity of any adverse events. </p> </section> <section id="CD011108-sec-0003"> <h3 class="title" id="CD011108-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase and clinical trials registers in November 2020. We applied no language, document type or publication status limitations to the search. </p> </section> <section id="CD011108-sec-0004"> <h3 class="title" id="CD011108-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared hydromorphone with placebo, an alternative opioid or another active control, for cancer pain in adults and children. Primary outcomes were participant‐reported pain intensity and pain relief; secondary outcomes were specific adverse events, serious adverse events, quality of life, leaving the study early and death. </p> </section> <section id="CD011108-sec-0005"> <h3 class="title" id="CD011108-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data. We calculated risk ratio (RR) and 95% confidence intervals (CI) for binary outcomes on an intention‐to‐treat (ITT) basis. We estimated mean difference (MD) between groups and 95% CI for continuous data. We used a random‐effects model and assessed risk of bias for all included studies. We assessed the evidence using GRADE and created three summary of findings tables. </p> </section> <section id="CD011108-sec-0006"> <h3 class="title" id="CD011108-sec-0006">Main results</h3> <p>With four new identified studies, the review includes a total of eight studies (1283 participants, with data for 1181 participants available for analysis), which compared hydromorphone with oxycodone (four studies), morphine (three studies) or fentanyl (one study). All studies included adults with cancer pain, mean age ranged around 53 to 59 years and the proportion of men ranged from 42% to 67.4%. We judged all the studies at high risk of bias overall because they had at least one domain with high risk of bias. </p> <p>We found no studies including children. We did not complete a meta‐analysis for the primary outcome of pain intensity due to skewed data and different comparators investigated across the studies (oxycodone, morphine and fentanyl). </p> <p><b>Comparison 1: hydromorphone compared with placebo</b> </p> <p>We identified no studies comparing hydromorphone with placebo.</p> <p><b>Comparison 2: hydromorphone compared with oxycodone</b> </p> <p><i>Participant‐reported pain intensity</i> </p> <p>We found no clear evidence of a difference in pain intensity (measured using a visual analogue scale (VAS)) in people treated with hydromorphone compared with those treated with oxycodone, but the evidence is very uncertain (3 RCTs, 381 participants, very low‐certainty evidence). </p> <p><i>Participant‐reported pain relief</i> </p> <p>We found no studies reporting participant‐reported pain relief.</p> <p><i>Specific adverse events</i> </p> <p>We found no clear evidence of a difference in nausea (RR 1.13 95% CI 0.74 to 1.73; 3 RCTs, 622 participants), vomiting (RR 1.18, 95% CI 0.72 to 1.94; 3 RCTs, 622 participants), dizziness (RR 0.91, 95% CI 0.58 to 1.44; 2 RCTs, 441 participants) and constipation (RR 0.92, 95% CI 0.72 to 1.19; 622 participants) (all very low‐certainty evidence) in people treated with hydromorphone compared with those treated with oxycodone, but the evidence is very uncertain. </p> <p><i>Quality of life</i> </p> <p>We found no studies reporting quality of life.</p> <p><b>Comparison 3: hydromorphone compared with morphine</b> </p> <p><i>Participant‐reported pain intensity</i> </p> <p>We found no clear evidence of a difference in pain intensity (measured using the Brief Pain Inventory (BPI) or VAS)) in people treated with hydromorphone compared with those treated with morphine, but the evidence is very uncertain (2 RCTs, 433 participants; very low‐certainty evidence). </p> <p><i>Participant‐reported pain relief</i> </p> <p>We found no clear evidence of a difference in the number of clinically improved participants, defined by 50% or greater pain relief rate, in the hydromorphone group compared with the morphine group, but the evidence is very uncertain (RR 0.99, 95% CI 0.84 to 1.18; 1 RCT, 233 participants; very low‐certainty evidence). </p> <p><i>Specific adverse events</i> </p> <p>At 24 days of treatment, morphine may reduce constipation compared with hydromorphone, but the evidence is very uncertain (RR 1.56, 95% CI 1.12 to 2.17; 1 RCT, 200 participants; very low‐certainty evidence). We found no clear evidence of a difference in nausea (RR 0.94, 95% CI 0.66 to 1.30; 1 RCT, 200 participants), vomiting (RR 0.87, 95% CI 0.58 to 1.31; 1 RCT, 200 participants) and dizziness (RR 1.15, 95% CI 0.71 to 1.88; 1 RCT, 200 participants) (all very low‐certainty evidence) in people treated with hydromorphone compared with those treated with morphine, but the evidence is very uncertain. </p> <p><i>Quality of life</i> </p> <p>We found no studies reporting quality of life.</p> <p><b>Comparison 4: hydromorphone compared with fentanyl</b> </p> <p><i>Participant‐reported pain intensity</i> </p> <p>We found no clear evidence of a difference in pain intensity (measured by numerical rating scale (NRS)) at 60 minutes in people treated with hydromorphone compared with those treated with fentanyl, but the evidence is very uncertain (1 RCT, 82 participants; very low‐certainty evidence). </p> <p><i>Participant‐reported pain relief</i> </p> <p>We found no studies reporting participant‐reported pain relief.</p> <p><i>Specific adverse events</i> </p> <p>We found no studies reporting specific adverse events.</p> <p><i>Quality of life</i> </p> <p>We found no studies reporting quality of life.</p> </section> <section id="CD011108-sec-0007"> <h3 class="title" id="CD011108-sec-0007">Authors' conclusions</h3> <p>The evidence of the benefits and harms of hydromorphone compared with other analgesics is very uncertain. The studies reported some adverse events, such as nausea, vomiting, dizziness and constipation, but generally there was no clear evidence of a difference between hydromorphone and morphine, oxycodone or fentanyl for this outcome. </p> <p>There is insufficient evidence to support or refute the use of hydromorphone for cancer pain in comparison with other analgesics on the reported outcomes. Further research with larger sample sizes and more comprehensive outcome data collection is required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011108-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011108-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011108-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011108-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011108-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011108-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011108-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011108-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011108-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011108-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011108-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011108-abs-0002" lang="en"> <h3>Hydromorphone for the treatment of cancer pain</h3> <p><b>Background</b> </p> <p>Over 75% of people with cancer experience pain. Around 30% to 50% of these people have moderate to severe pain, which can have a negative impact on daily life. Cancer pain is a distressing symptom that tends to worsen as the disease progresses. Hydromorphone may help relieve these symptoms. Cancer‐related pain is usually treated with medicines such as morphine, oxycodone, fentanyl or hydromorphone. This review looked at the benefits and harms of hydromorphone compared with other medicines. </p> <p><b>Study characteristics</b> </p> <p>In November 2020, we updated our searches for randomised controlled studies of hydromorphone compared with placebo, an alternative opioid or another active control. Randomised controlled studies are studies where people are randomly placed into different treatment groups. We found four studies that compared hydromorphone with oxycodone, three studies that compared hydromorphone with morphine and one study that compared hydromorphone with fentanyl. </p> <p><b>Results</b> </p> <p>This review includes eight studies (four new studies included in this updated version) with 1283 participants comparing hydromorphone with oxycodone, morphine or fentanyl in adults (aged 18 years and above) with moderate to severe cancer pain. None of the studies compared hydromorphone and placebo. None of the studies included children. </p> <p>We found no differences in pain intensity scores between the different treatment groups and on average patients reported low levels of pain after opioid administration. Hydromorphone seemed to work as well as morphine, oxycodone and fentanyl. There were some side effects, such as nausea, vomiting, dizziness and constipation, but generally there was no clear difference between people taking hydromorphone and people taking morphine, oxycodone or fentanyl. </p> <p><b>Certainty of the evidence</b> </p> <p>We rated the certainty of the evidence from studies using four levels: very low, low, moderate or high. Very low‐certainty evidence means that we are very uncertain about the results. High‐certainty evidence means that we are very confident in the results. No results were rated as high certainty; we only identified very low‐certainty evidence for pain intensity, pain relief and side effects. These outcomes were rated as very low certainty because there were either few trials included with few participants, or due to other sources of bias, such as potential competing interests with the pharmaceutical industry. </p> <p><b>Conclusions</b> </p> <p>The studies did not provide enough high‐certainty evidence to draw firm conclusions; the evidence of the benefits and harms of hydromorphone compared with other medicines is very uncertain. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011108-sec-0101" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011108-sec-0101"></div> <h3 class="title" id="CD011108-sec-0102">Implications for practice</h3> <section id="CD011108-sec-0102"> <section id="CD011108-sec-0103"> <h5 class="title">For people with cancer pain</h5> <p>Based on data gathered from the eight included trials, it appears that hydromorphone has a similar effect on participant‐reported pain intensity as oxycodone, morphine and fentanyl for adults with moderate to severe cancer pain. There was no evident comparative difference in analgesic effect between hydromorphone and other opioids investigated in this review and the mean postintervention pain scores were generally below the threshold for 'no worse than mild pain' on all investigated treatments. There were several adverse events, but generally there was no difference between groups. In summary, there is no clear evidence of a difference between hydromorphone and oxycodone, morphine or fentanyl in adults with moderate to severe cancer pain. However, this finding should be applied with caution for our review included only eight studies, which had different designs and limited sample sizes. The evidence of the benefits and harms of hydromorphone compared with oxycodone, morphine and fentanyl is very uncertain. There were no data available for children or for some important outcomes such as quality of life. </p> </section> <section id="CD011108-sec-0104"> <h5 class="title">For clinicians</h5> <p>Based on eight included trials with different designs and limited number of participants, we found a lack of evidence to support a preference for hydromorphone over other opioid analgesics such as morphine, oxycodone and fentanyl. The treatment effect of hydromorphone appeared to be similar to that of the comparator drugs for adults with moderate to severe cancer pain. There were minor adverse events in all treatment groups and generally no clear evidence of a difference between groups. However, most of the outcome data were based on single randomised controlled trials with small sample sizes, thus the findings of the current review should be interpreted and applied with caution. We found no data for children. The insufficient evidence requires clinicians to balance potential benefits against potential adverse events on the merit of each individual case when recommending treatment in clinical practice. </p> </section> <section id="CD011108-sec-0105"> <h5 class="title">For policy makers</h5> <p>This review identified little evidence to support hydromorphone as the first‐, second‐ or third‐line treatment for cancer pain. However, evidence collated in the current review suggests hydromorphone has a similar analgesic effect as morphine, oxycodone and fentanyl, it can be considered as an alternative when other opioids result in excessive adverse events such as sedation and respiratory depression, and when people with cancer pain experience renal failure. We found no data for children. Included studies were conducted in high‐income countries, which may compromise the external validity of the review as some of the drugs investigated may have limited accessibility in some lower‐income countries. Finally, it is worth noting that findings from the current review are mainly based on small trials with different designs and limited sample size and some risk of bias, therefore, should be applied with caution. </p> </section> </section> <h3 class="title" id="CD011108-sec-0106">Implications for research</h3> <section id="CD011108-sec-0106"> <p>This review confirms a general lack of research in this subject area, with poor and inconsistent reporting of adverse events and low trial sizes. <a href="./references#CD011108-bbs2-0077" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592.pub2]">Wiffen 2017a</a> suggest some core outcomes that can help decisions in clinical practice, for instance, the proportion of participants reporting no worse than mild pain on treatment by 14 days after start of treatment, Patient Global Impression of Change (PGIC) of much or very much improved. These outcomes are seldomly reported by the included studies. Future trials with significant numbers of participants (e.g. more than 200 per treatment arm) are needed to evaluate important outcomes of hydromorphone for the management of moderate to severe cancer pain in adults. Future research is encouraged to involve children and young adults to provide direct evidence in this population. Further adequately powered randomised controlled trials should use standardised tools or scales to measure pain as a primary outcome. More data on other secondary outcomes, as well as the comparative effect of a more comprehensive range of medications, would also be useful to enable the review to draw a more reliable and conclusive effect. Longer‐term toxicity data should be collected if possible. </p> <p>Prevalence of sleep disturbance in people with cancer ranges from 24% to 95% (<a href="./references#CD011108-bbs2-0036" title="GraciG . Pathogenesis and management of cancer-related insomnia. Journal of Supportive Oncology2005;3(5):349-59. [PMID: 16218258]">Graci 2005</a>; <a href="./references#CD011108-bbs2-0051" title="MercadanteS , GirelliD , CasuccioA . Sleep disorders in advanced cancer patients: prevalence and factors associated. Supportive Care in Cancer2004;12(5):355-9. [PMID: 15064937]">Mercadante 2004</a>), and is more common among females with cancer, older people, and people with depression or anxiety (<a href="./references#CD011108-bbs2-0027" title="AkechiT , OkuyamaT , AkizukiN , ShimizuK , InagakiM , FujimoriM , et al. Associated and predictive factors of sleep disturbance in advanced cancer patients. Psycho-oncology2007;16(10):888-94. [PMID: 17086580]">Akechi 2007</a>; <a href="./references#CD011108-bbs2-0036" title="GraciG . Pathogenesis and management of cancer-related insomnia. Journal of Supportive Oncology2005;3(5):349-59. [PMID: 16218258]">Graci 2005</a>). Therefore, we suggest that more attention is given to pain control for increasing quality of sleep and quality of life (<a href="./references#CD011108-bbs2-0036" title="GraciG . Pathogenesis and management of cancer-related insomnia. Journal of Supportive Oncology2005;3(5):349-59. [PMID: 16218258]">Graci 2005</a>; <a href="./references#CD011108-bbs2-0048" title="KvaleEA , ShusterJL . Sleep disturbance in supportive care of cancer: a review. Journal of Palliative Medicine2006;9(2):437-50. [PMID: 16629573]">Kvale 2006</a>), especially the effect of OROS (osmotic‐controlled release oral delivery system) hydromorphone for people with cancer pain with sleep disturbance. The absence of the outcome quality of life may indicate a research gap in the field. Further high‐quality randomised controlled trials are expected to define quality of life as an important outcome in trials. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011108-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011108-sec-0008"></div> <div class="table" id="CD011108-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hydromorphone compared with oxycodone for people with moderate to severe cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hydromorphone compared with oxycodone for people with moderate to severe cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with moderate to severe cancer pain </p> <p><b>Setting:</b> unclear, not specified in included studies </p> <p><b>Intervention:</b> hydromorphone </p> <p><b>Comparison:</b> oxycodone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oxycodone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hydromorphone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain intensity</b> (as measured by VAS or BPI) </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>For pain intensity, the results were similar in hydromorphone and oxycodone groups, although data were skewed. Only 1 study showed mean pain levels of 'no worse than mild pain' for oxycodone and hydromorphone groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>462<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity scores: 3 studies (n = 381) using VAS (0–100, higher = worse outcome): mean endpoint score for hydromorphone in each study was 28.86 (SD 17.08, n = 19); 23 (SD 17.91, n = 86); 24.7 (SD 22.1, n = 88). Mean endpoint score for oxycodone in each study was 30.30 (SD 25.33, n = 12); 23.2 (SD 18.83, n = 92); 27.9 (SD 21.05, n = 84). 1 study using BPI (0–10; higher = worse outcome): mean change score of 'pain at its worst in the past 24 hours' for hydromorphone −1.8 (SD 3.29, n = 81). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – nausea</b> </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.13</b><br/>(0.74 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>326 per 1000<br/>(213 to 499) more </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<br/>(175 to 409) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – vomiting</b> </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.18</b><br/>(0.72 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000<br/>(203 to 547) more </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/>(162 to 436) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – dizziness</b> </p> <p>Follow‐up: 7–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b><br/>(0.58 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>441<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000<br/>(83 to 207) fewer </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000<br/>(77 to 191) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – constipation</b> </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b><br/>(0.72 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000<br/>(203 to 336) fewer </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000<br/>(194 to 321) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BPI:</b> Brief Pain Inventory; <b>CI:</b> confidence interval; <b>n:</b> number of participants; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to very serious study limitations: studies were rated at high risk of bias overall, mainly accounted for by attrition bias and funding bias.<br/><sup>b</sup>Downgraded once due to serious imprecision: all studies had fewer than 200 participants in each treatment arm. Also sample size was smaller than optimal information size (GRADE guidelines 6, <a href="./references#CD011108-bbs2-0039" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>); CIs around estimate of effect were wide and included null effect and appreciable benefit/harm.<br/><sup>c</sup>Decision taken not to downgrade due to publication bias: although publication bias was highly suspected due to the small number of trials identified, this outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate.<br/><sup>d</sup>Decision taken not to downgrade due to inconsistency: although inconsistency was highly suspected due to I<sup>2</sup> value greater than 50% with unexplainable heterogeneity, this outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011108-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hydromorphone compared with morphine for people with moderate to severe cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hydromorphone compared with morphine for people with moderate to severe cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with moderate to severe cancer pain </p> <p><b>Setting:</b> inpatients, outpatients and day patients </p> <p><b>Intervention:</b> hydromorphone </p> <p><b>Comparison:</b> morphine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with morphine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hydromorphone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain intensity</b> (as measured by BPI and VAS) </p> <p>Follow‐up: 12 weeks</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>For pain intensity measured by BPI at 24 days, the results showed slightly higher mean endpoint scores for 'worst pain' in morphine group and similar mean scores for 'average' and 'least' pain in hydromorphone and morphine groups. For pain intensity measured by VAS from weeks 1–12, both morphine and hydromorphone groups had mean pain levels of 'no worse than mild pain.' Evidence of hydromorphone vs morphine on pain intensity was very uncertain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study (n = 200) using subscale data derived from BPI scale (0–10; higher = worse outcome): mean endpoint score for 'worst pain:' hydromorphone 3.5 (SD 2.9, n = 99); morphine 4.3 (SD 3.0, n = 101). Mean scores on 'least pain' and 'average pain' were almost identical. 1 study (n = 233) using VAS scale (0–10; higher = worse outcome) measured pain intensity from week 1 to week 12 of treatment. Both groups had identical scores at all the measured timepoints (P &gt; 0.05). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant‐reported pain relief</b> </p> <p>Follow‐up: mean 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b><br/>(0.84 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>705 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>698 per 1000<br/>(593 to 832) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific adverse events – nausea</b> </p> <p>Follow‐up: 24 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b><br/>(0.66 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>396 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372 per 1000<br/>(261 to 515) fewer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific adverse events – vomiting</b> </p> <p>Follow‐up: 24 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.87</b><br/>(0.58 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>337 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000<br/>(195 to 441) fewer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific adverse events – dizziness</b><br/>Follow‐up: 24 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/>(0.71 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/>(162 to 428) more </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – constipation</b><br/>Follow‐up: 24 days to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The higher incidence of constipation of hydromorphone occurred at a shorter treatment point (at 24 days of treatment), but not a longer treatment point (12 weeks). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported the incidence of constipation at different timepoints. 1 study (n = 200) measured at 24 days of treatment found a significantly higher incidence of constipation with hydromorphone than with morphine (RR 1.56, 95% CI 1.12 to 2.17; P = 0.009). 1 study (n = 233) measured at 12 weeks' follow‐up found no clear difference between 2 groups (RR 0.65, 95% CI 0.42 to 1.00; P = 0.055). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BPI:</b> Brief Pain Inventory; <b>CI:</b> confidence interval; <b>n:</b> number of participants; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to very serious study limitations: all studies were rated at high risk of bias for at least two domains.<br/><sup>b</sup>Downgraded once due to serious imprecision: studies contained fewer than 200 participants in each treatment arm, and sample size was smaller than optimal information size (<a href="./references#CD011108-bbs2-0039" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>); CI around estimate of effect was wide and included no effect and appreciable benefit/harm.<br/><sup>c</sup>Decision made not to downgrade due to publication bias: although publication bias was highly suspected due to the small number of trials identified, this outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011108-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hydromorphone compared with fentanyl for people with moderate to severe cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Hydromorphone compared with fentanyl for people with moderate to severe cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with moderate to severe cancer pain </p> <p><b>Setting:</b> included studies did not specify inpatients, outpatients or community settings </p> <p><b>Intervention:</b> hydromorphone </p> <p><b>Comparison:</b> fentanyl </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain intensity</b> (as measured by NRS)<br/>Follow‐up: mean 1 day </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 study (n = 82) measured pain intensity using NRS at 60 minutes after treatment initiation. The mean decrease from pain score at randomisation showed no clear difference between the 2 groups (MD −0.24, 95% CI −1.21 to 0.73; P = 0.63). In addition, the mean decrease from maximum pain score of 10 for the hydromorphone group and from randomisation pain score for the fentanyl group showed no clear difference (MD 0.81, 95% CI −0.18 to 1.80; P = 0.11). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – dizziness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – constipation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>n:</b> number of participants; <b>MD:</b> mean difference; <b>NRS:</b> numerical rating scale; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to very serious study limitations: study was rated at high risk of bias for at least two domains.<br/><sup>b</sup>Downgraded once due to serious imprecision: CIs around estimate of effect were wide and included null effect and appreciable benefit/harm.<br/><sup>c</sup>Decision made not to downgrade due to publication bias: although publication bias was highly suspected due to the small number of trials identified, this outcome had already been downgraded three times by other factors, therefore further downgrade would be inappropriate. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011108-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011108-sec-0009"></div> <p>This is an update of a previously published review in the Cochrane Library entitled 'Hydromorphone for cancer pain' (<a href="./references#CD011108-bbs2-0081" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , KnaggsR . Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016;CD01110(10):DOI: 10.1002/14651858.CD011108.pub2.">Bao 2016</a>). The previous review updated and replaced the published 'Hydromorphone for acute and chronic pain' review, which was withdrawn because the original author team were unavailable to update it (<a href="./references#CD011108-bbs2-0082" title="QuigleyC . Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews2013, Issue 10. Art. No: CD003447. [DOI: 10.1002/14651858.CD003447.pub2]">Quigley 2013</a>). The scope of the current review is limited to cancer pain. </p> <section id="CD011108-sec-0010"> <h3 class="title" id="CD011108-sec-0010">Description of the condition</h3> <p>Pain is defined as "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage" (<a href="./references#CD011108-bbs2-0044" title="RajaSN , CarrDB , CohenM , FinnerupNB , FlorH , GibsonS , et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain2020;161(9):1976-82.">IASP 2020</a>). Cancer‐related pain can be classified as acute or chronic, though it is sometimes thought to be an ongoing acute pain. Acute pain is defined as having "a temporal pattern of onset … generally associated with subjective and objective physical signs" (<a href="./references#CD011108-bbs2-0050" title="MeierDE , IsaacsSL , HughesR . Palliative Care: Transforming the Care of Serious Illness. 1st edition. San Francisco (CA): Jossey-Bass, 2010.">Meier 2010</a>), whereas chronic pain is more continuous, and lasts or recurs for more than three months (<a href="./references#CD011108-bbs2-0045" title="TreedeRD , RiefW , BarkeA , AzizQ , BennettMI , BenolielR , et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain2019;160(1):19-27.">ICD‐11 2019</a>). Although pain is not necessarily inevitable for people who are diagnosed with cancer, it is an important and distressing common symptom of the disease, which tends to increase in frequency and intensity as the cancer advances. One previous systematic review indicated the prevalence of pain to be more than 50% in all cancer types (<a href="./references#CD011108-bbs2-0070" title="Van den Beuken-van EverdingenMH , De RijkeJM , KesselsAG , SchoutenHC , vanKleefM , PatijnJ . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Annals of Oncology2007;18(9):1437-49.">Van den Beuken‐van Everdingen 2007</a>). For people with advanced cancer, the prevalence of pain can be as high as 90% (<a href="./references#CD011108-bbs2-0049" title="LairdB , ColvinL , FallonM . Management of cancer pain: basic principles and neuropathic cancer pain. European Journal of Cancer2008;44:1078-82.">Laird 2008</a>). One more recent systematic review reported a prevalence rate of 66.4% in advanced, metastatic or terminal disease; 40% after curative treatment; and 55% during anticancer treatment, which indicates that the prevalence of cancer pain remains high (<a href="./references#CD011108-bbs2-0071" title="Van den Beuken-VanMH , HochstenbachLM , JoostenEA , Tjan-HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of Pain and Symptom Management2016;51(6):1070-90.">Van den Beuken‐Van MH 2016</a>). </p> <p>Epidemiological studies suggest that approximately 15% of people with cancer who experience pain fail to achieve acceptable pain relief with conventional management (<a href="./references#CD011108-bbs2-0064" title="RunningA , TurnbeaughE . Oncology pain and complementary therapy. Clinical Journal of Oncology Nursing2011;15(4):374-9.">Running 2011</a>; <a href="./references#CD011108-bbs2-0080" title="YakovlevAE , ElliaY . Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clinical Medicine &amp; Research2008;6(3-4):103-6.">Yakovlev 2008</a>). It has been estimated that 30% to 50% of people with cancer categorise their pain as moderate to severe and that between 75% and 90% of people with cancer experience pain which has a major impact on their daily life (<a href="./references#CD011108-bbs2-0059" title="PortenoyRK , LesageP . Management of cancer pain. Lancet1999;353:1695-700. [DOI: 10.1016/S0140-6736(99)01310-0]">Portenoy 1999</a>). Uncontrolled pain can lead to physical and psychological distress (<a href="./references#CD011108-bbs2-0071" title="Van den Beuken-VanMH , HochstenbachLM , JoostenEA , Tjan-HeijnenVC , JanssenDJ . Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. Journal of Pain and Symptom Management2016;51(6):1070-90.">Van den Beuken‐Van MH 2016</a>), and can have a drastic effect on people's quality of life (<a href="./references#CD011108-bbs2-0038" title="GreenCR , Hart-JohnsonT , LoefflerDR . Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer2011;117(9):1994-2003.">Green 2011</a>). </p> </section> <section id="CD011108-sec-0011"> <h3 class="title" id="CD011108-sec-0011">Description of the intervention</h3> <p>The use of interventions for managing cancer pain, including pharmacological treatments (e.g. opioid analgesics), psychological therapy (e.g. cognitive behavioural therapy) and alternative treatments (e.g. acupuncture or massage), commonly rely on recommendations given by clinical practice guidelines. </p> <p>The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines gives recommendations for adults according to the severity of cancer pain (<a href="./references#CD011108-bbs2-0035" title="FallonM , GiustiR , AielliF , HoskinP , RolkeR , SharmaM , et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology2018;29(Suppl 4):iv166-iv191.">ESMO 2018</a>) based on data from the World Health Organization (WHO) recommendations (<a href="./references#CD011108-bbs2-0073" title="World Health Organization. Cancer Pain Relief. 2nd edition. Geneva: WHO, 1986.">WHO 1986</a>). For treatment of mild pain, paracetamol and non‐steroidal anti‐inflammatory drugs (NSAIDs) are recommended; for treatment of mild to moderate pain, weak opioids (e.g. tramadol, dihydrocodeine and codeine) are recommended with a combination of non‐opioid analgesics; for treatment of moderate to severe pain, strong opioids are recommended, and the first choice is oral morphine (<a href="./references#CD011108-bbs2-0041" title="HanksGW , De ConnoF , ChernyN , HannaM , KalsoE , McQuayHJ , et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. British Journal of Cancer2001;84(5):587-93.">Hanks 2001</a>). This recommendation is largely due to its cost and availability rather than proven superiority (<a href="./references#CD011108-bbs2-0032" title="CaraceniA , HanksG , KaasaS , BennettMI , BrunelliC , ChernyN , et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology2012;13(2):e58-68.">Caraceni 2012</a>), with a previous review suggesting that a clear proportion of people do not achieve sufficient pain relief by taking morphine due to unmanageable adverse events, including nausea, delirium or myoclonus (muscle spasm) (<a href="./references#CD011108-bbs2-0055" title="MurrayA , HagenNA . Hydromorphone. Journal of Pain and Symptom Management2005;29(5):57-66.">Murray 2005</a>). However, evidence from one Cochrane Review on oral morphine for cancer pain suggested that only around 5% of participants stopped taking morphine due to lack of pain relief or unacceptable adverse events (<a href="./references#CD011108-bbs2-0076" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD003868. [DOI: 10.1002/14651858.CD003868.pub3]">Wiffen 2013</a>). Morphine has also been associated with toxicity in people with renal impairment (<a href="./references#CD011108-bbs2-0046" title="KingS , ForbesK , HanksGW , FerroCJ , ChambersEJ . A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative Medicine2011;25(5):525-52.">King 2011a</a>). In the National Comprehensive Cancer Network (NCCN) guidelines for adult cancer pain, the use of opioids is also recommended according to severity of pain; and the recommended dose of opioids is introduced in morphine sulphate or equivalent (<a href="./references#CD011108-bbs2-0056" title="National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis. Version 1.2021. www.nccn.org/guidelines/guidelines-detail?category=3&amp;id=1415 (accessed 18 June 2021).">NCCN 2021</a>). </p> <p>In 2019, the WHO updated the guideline for pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. The new guideline recommends considering the use of non‐opioids (e.g. paracetamol or NSAIDs) for the initiation of pain relief; for the maintenance of pain relief, any weak or strong opioid (e.g. codeine, morphine, methadone, hydromorphone, oxycodone or fentanyl) or a combination of opioids with NSAIDs should be considered depending on clinical assessment and pain severity (<a href="./references#CD011108-bbs2-0074" title="World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents, 2019. www.who.int/publications/i/item/9789241550390 (accessed prior to 18 June 2021).">WHO 2019a</a>). It is noteworthy that the latest WHO guideline states that the choice of opioid analgesic may make little or no difference in speed of pain relief, duration of maintenance of pain reduction or functional outcomes. </p> <p>However, partially due to the recommendation of the use of opioids in the management of cancer pain in most international clinical guidelines, the prescriptions for opioids for pain relief increased (<a href="./references#CD011108-bbs2-0040" title="HanBH , ShermanSE , PalamarJJ . Prescription opioid misuse among middle-aged and older adults in the United States, 2015-2016. Preventive Medicine2019;121:94-8.">Han 2019</a>). The side effect of opioid overdose can cause opioid dependence and other health problems (<a href="./references#CD011108-bbs2-0075" title="WHO. International Classification of Diseases for Mortality and Morbidity Statistics. 11th edition. Geneva: World Health Organization, 2019.">WHO 2019b</a>). Although one report indicated that the opioid overdose mortality rate decreased in the US during 2017 to 2018, it is still a noteworthy issue since the rate of overdose mortality involving synthetic opioids, mainly accounted for by fentanyl, increased relatively (<a href="./references#CD011108-bbs2-0079" title="WilsonN , KariisaM , SethP , Smith H 4th, DavisNL . Drug and opioid-involved overdose deaths – United States, 2017–2018. MMWR. Morbidity and Mortality Weekly Report2020;69:290-7.">Wilson 2020</a>). </p> <p>Hydromorphone (also known as dihydromorphinone) is a semi‐synthetic derivative of morphine and is marketed in various countries under a range of brand names. Since its clinical introduction in 1926, it has been used as an alternative opioid analgesic to morphine, as it has a similar chemical structure but is more lipid soluble (<a href="./references#CD011108-bbs2-0069" title="UrquhartML , KlappK , WhitePF . Patient controlled analgesia: a comparison of intravenous versus subcutaneous hydromorphone. Anesthesiology1988;69:428-32.">Urquhart 1988</a>) and potent (<a href="./references#CD011108-bbs2-0068" title="TwycrossRG . Pain Relief in Advanced Cancer. Singapore: Churchill Livingstone, 1994.">Twycross 1994</a>). Hydromorphone hydrochloride has high aqueous solubility and is beneficial for people who require higher doses (<a href="./references#CD011108-bbs2-0060" title="PortenoyRK . Treatment of cancer pain. Lancet2011;377(9784):2236-47.">Portenoy 2011</a>), and OROS (osmotic‐controlled release oral delivery system) hydromorphone extended release (ER) is five times as potent as morphine, and has 8.5 times the equianalgesic effect when administered intravenously (<a href="./references#CD011108-bbs2-0030" title="BinsfeldH , SzczepanskiL , WaechterS , RicharzU , SabatowskiR . A randomized study to demonstrate noninferiority of once-daily OROS® hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Practice2010;10(5):404-15.">Binsfeld 2010</a>; <a href="./references#CD011108-bbs2-0065" title="SarhillN , WalshD , NelsonKA . Hydromorphone: pharmacology and clinical applications in cancer patients. Supportive Care Cancer2001;9(2):84-96.">Sarhill 2001</a>). This also allows a smaller dose of hydromorphone to be used for an equianalgesic effect. Hydromorphone is administered through several routes (e.g. oral, intravenous, subcutaneous, epidural and intrathecal) (<a href="./references#CD011108-bbs2-0055" title="MurrayA , HagenNA . Hydromorphone. Journal of Pain and Symptom Management2005;29(5):57-66.">Murray 2005</a>). </p> </section> <section id="CD011108-sec-0012"> <h3 class="title" id="CD011108-sec-0012">How the intervention might work</h3> <p>Like morphine, hydromorphone is primarily an agonist at μ‐opioid receptors, displaying weak affinity for κ‐opioid receptors. μ‐Opioid receptors mediate pain‐relieving properties but they can also result in adverse events such as nausea, constipation and respiratory depression (<a href="./references#CD011108-bbs2-0055" title="MurrayA , HagenNA . Hydromorphone. Journal of Pain and Symptom Management2005;29(5):57-66.">Murray 2005</a>). One systematic review showed that hydromorphone had similar analgesic and adverse effects to morphine (<a href="./references#CD011108-bbs2-0052" title="MillerMG , McCarthyN , O'BoyleCA , KearneyM . Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. Journal of Pain and Symptom Management1999;18(1):9-16.">Miller 1999</a>), while recent reviews concluded that no study has yet clearly demonstrated whether hydromorphone is better than oral morphine (<a href="./references#CD011108-bbs2-0058" title="PigniA , BrunelliC , CaraceniA . The role of hydromorphone in cancer pain treatment: a systematic review. Palliative Medicine2011;25(5):471-7.">Pigni 2011</a>; <a href="./references#CD011108-bbs2-0067" title="SchusterM , BayerO , HeidF , Laufenberg-FeldmannR . Opioid Rotation in Cancer Pain Treatment: A Systematic Review.. Deutsches Ärzteblatt International2018;115(9):135.">Schuster 2018</a>). </p> <p>Hydromorphone, in common with other opioid analgesics, has the potential to produce adverse events that include respiratory depression, nausea, vomiting, constipation and itching. Tolerance may develop during chronic opioid therapy such that larger doses may be required to sustain the analgesic effect. In addition, people can be at risk of physiological dependence and experience opioid withdrawal syndrome upon sudden cessation of the opioid or administration of an antagonist. When used for the relief of pain in malignant disease, the actions of relieving anxiety, producing drowsiness and allowing sleep may be welcome (<a href="./references#CD011108-bbs2-0037" title="Grahame-SmithDG , AronsonJK . Oxford Textbook of Clinical Pharmacology and Drug Therapy. 3rd edition. Oxford: Oxford University Press, 2002.">Grahame‐Smith 2002</a>). </p> </section> <section id="CD011108-sec-0013"> <h3 class="title" id="CD011108-sec-0013">Why it is important to do this review</h3> <p>This is one of a suite of Cochrane Reviews investigating analgesics for cancer pain in adults (<a href="./references#CD011108-bbs2-0033" title="DerryS , WiffenPJ , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012638. [DOI: 10.1002/14651858.CD012638.pub2]">Derry 2017</a>; <a href="./references#CD011108-bbs2-0042" title="HaywoodA , GoodP , KhanS , LeuppA , Jenkins-MarshS , RickettK , et al. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database of Systematic Reviews2015, Issue 4. Art. No: CD010756. [DOI: 10.1002/14651858.CD010756.pub2]">Hardy 2015</a>; <a href="./references#CD011108-bbs2-0076" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD003868. [DOI: 10.1002/14651858.CD003868.pub3]">Wiffen 2013</a>; <a href="./references#CD011108-bbs2-0077" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592.pub2]">Wiffen 2017a</a>; <a href="./references#CD011108-bbs2-0078" title="WiffenPJ , DerryS , MooreRA , McNicolED , BellRF , CarrDB , et al. Oral paracetamol (acetaminophen) for cancer pain. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012637. [DOI: 10.1002/14651858.CD012637.pub2]">Wiffen 2017b</a>). Although the WHO recommends oral morphine as a first‐line analgesia for cancer‐related pain, the use of hydromorphone remains a consideration in some circumstances (<a href="./references#CD011108-bbs2-0076" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD003868. [DOI: 10.1002/14651858.CD003868.pub3]">Wiffen 2013</a>). Previous systematic reviews have compared the efficacy and adverse effects of hydromorphone with other medications, but the inconsistency of their conclusions and the limited (low to moderate) methodological quality of the studies that were included suggested that further research is needed (<a href="./references#CD011108-bbs2-0058" title="PigniA , BrunelliC , CaraceniA . The role of hydromorphone in cancer pain treatment: a systematic review. Palliative Medicine2011;25(5):471-7.">Pigni 2011</a>). </p> <p>Our previous review in 2016 included four trials with limited data and indicated little difference between hydromorphone and other opioids, including morphine and oxycodone, in terms of analgesic efficacy and safety. The overall quality of evidence was relatively very low due to risk of bias, imprecision of effect estimates and publication bias. </p> <p>During the previous four years, more trials might have been conducted to help determine the effectiveness and safety of different opioids due to the changes made to the definition of pain and the new updated international clinical guidelines. This new evidence may change the estimates of effect. Therefore, we aimed to update the review by searching for evidence between 2016 and 2020 in order to provide an up‐to‐date and more comprehensive result. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011108-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011108-sec-0014"></div> <p>To determine the analgesic efficacy of hydromorphone in relieving cancer pain, as well as the incidence and severity of any adverse events. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011108-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011108-sec-0015"></div> <section id="CD011108-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011108-sec-0017"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) are the best design to minimise bias when evaluating the effectiveness of an intervention. We included RCTs that focused on hydromorphone for the treatment of cancer pain and assessed pain as an outcome measure in this review. The RCTs included parallel or cross‐over studies of any duration. We excluded studies that did not state that participants were allocated at random. </p> </section> <section id="CD011108-sec-0018"> <h4 class="title">Types of participants</h4> <p>We intended to include studies of adults and children with moderate to severe cancer pain (as defined in each study) who were clinically assessed as requiring treatment with opioid analgesia. </p> <p>One of the reasons for including adults and children with moderate to severe cancer pain is that these people may experience increased and stronger negative impacts such as poorer sleeping quality, depression and emotional impacts, whereas people with mild pain are more likely to tolerate these negative impacts. In addition, hydromorphone is categorised as a strong opioid, which is stated clearly in international guidelines that is recommended to manage moderate to severe pain. </p> </section> <section id="CD011108-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included studies in which hydromorphone (any dose and route of administration) was the active intervention. Comparison treatments included placebo, an alternative opioid or another active control. </p> </section> <section id="CD011108-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We assessed participant‐reported pain intensity and pain relief using any validated pain scales (e.g. visual analogue scale (VAS) and categorical scales), at any timepoint. </p> <section id="CD011108-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011108-list-0001"> <li> <p>Participant‐reported pain intensity levels measured using a validated VAS or categorical pain scale. We were particularly interested in, but not limited to, numbers of participants who achieved 'no worse than mild pain' (<a href="./references#CD011108-bbs2-0054" title="MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs – 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12.">Moore 2013</a>). "No or mild pain" has been previously considered as: 3/10 on a numerical rating scale, or 30/100 mm on a VAS (<a href="./references#CD011108-bbs2-0076" title="WiffenPJ , WeeB , MooreRA . Oral morphine for cancer pain. Cochrane Database of Systematic Reviews2013, Issue 7. Art. No: CD003868. [DOI: 10.1002/14651858.CD003868.pub3]">Wiffen 2013</a>). We did not consider physician, nurse or carer‐reported measures of pain. </p> </li> <li> <p>Participant‐reported pain relief measured using a validated scale.</p> </li> </ul> </p> </section> <section id="CD011108-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011108-list-0002"> <li> <p>Specific adverse events, for example, drowsiness/sedation, nausea, vomiting, dizziness, constipation (incidence and severity, as defined and measured in each study). </p> </li> <li> <p>Serious adverse events (SAE), as defined and reported in each study.</p> </li> <li> <p>Improvement in participants' quality of life measured using the EuroQol EQ‐5D, the WHO Quality of Life Assessment or a similar validated quality of life instrument. </p> </li> <li> <p>Leaving the study early or discontinuation of treatment for any reason.</p> </li> <li> <p>Death.</p> </li> </ul> </p> </section> </section> </section> <section id="CD011108-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011108-sec-0024"> <h4 class="title">Electronic searches</h4> <p>For this update, we searched the following databases to identify potentially relevant studies to be assessed for inclusion in this review. See <a href="./appendices#CD011108-sec-0110">Appendix 1</a> for previous search strategies. See <a href="./appendices#CD011108-sec-0111">Appendix 2</a> for update search strategies from April 2016 to 23 November 2020. </p> <p> <ul id="CD011108-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), CRSO, April 2016 to November 2020. </p> </li> <li> <p>MEDLINE (Ovid) April 2016 to 23 November 2020.</p> </li> <li> <p>Embase (Ovid) April 2016 to 23 November 2020.</p> </li> </ul> </p> </section> <section id="CD011108-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We manually checked the references of each included paper in an attempt to identify any relevant published or unpublished reports not found in the electronic searches. We contacted the authors of each included paper and of publications that were only available in abstract format. Where possible, we contacted representatives from the pharmaceutical companies marketing hydromorphone to ask for any relevant published or unpublished studies or missing data. </p> <p>There were no limitations on publication date or language. We planned to translate any non‐English papers had this been necessary. We also searched for ongoing trials in ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the WHO registry (International Clinical Trials Registry Platform; ICTRP) (<a href="https://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>). </p> </section> </section> <section id="CD011108-sec-0026"> <h3 class="title" id="CD011108-sec-0026">Data collection and analysis</h3> <section id="CD011108-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (YL and YLiq) assessed the titles and abstracts of all studies identified by the searches and independently considered the full records of all potentially relevant studies for inclusion by applying the selection criteria outlined in the <a href="#CD011108-sec-0016">Criteria for considering studies for this review</a> section. We resolved disagreements by discussion. We did not restrict the inclusion criteria by date or language. To promote transparency of the search and systematic review process, we produced a PRISMA flow diagram (<a href="#CD011108-fig-0001">Figure 1</a>), as per the PRISMA statement (<a href="./references#CD011108-bbs2-0053" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):1-6.">Moher 2009</a>). </p> <div class="figure" id="CD011108-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (update)." data-id="CD011108-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (update).</p> </div> </div> </div> </section> <section id="CD011108-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted data using the Cochrane Pain, Palliative and Supportive Care Group's recommended data extraction form and recorded baseline data on participants, details of interventions, outcomes and results relevant to our review. Had we identified any studies that included a subset of participants who received hydromorphone, we planned to extract data for this group. We resolved any disputes by discussion. </p> </section> <section id="CD011108-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ZD and GL) independently assessed the methodological quality of each included study using the risk of bias assessment method outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>), with any disagreements resolved by discussion. We completed a risk of bias table for each included study using the risk of bias tool in Review Manager 5 (<a href="./references#CD011108-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). </p> <p>We assessed the following domains for each study.</p> <p> <ul id="CD011108-list-0004"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (any truly random process, e.g. random number table; computer random number generator) or unclear risk of bias (method used to generate sequence not clearly stated). We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed the methods as: low risk of bias (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes) or unclear risk of bias (method not clearly stated). We excluded studies that did not conceal allocation (e.g. open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and personnel from knowledge of which intervention a participant received. We assessed methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, such as identical tablets matched in appearance or smell, or a double‐dummy technique) or unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We considered studies that were not double‐blind to have high risk of bias. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (study had a clear statement that outcome assessors were unaware of treatment allocation, and ideally described how this was achieved); unclear risk of bias (study states that outcome assessors were blind to treatment allocation but lacked a clear statement on how it was achieved). We considered studies where outcome assessment was not blinded as having a high risk of bias. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk (less than 10% of participants did not complete the study or used 'baseline observation carried forward' analysis (BOCF), or both); unclear risk of bias (used 'last observation carried forward' analysis) or high risk of bias (used 'completer' analysis). </p> </li> <li> <p>Selective reporting (checking for reporting bias). We assessed whether primary and secondary outcome measures were prespecified and whether these were consistent with those reported: we assessed as low risk those studies that prespecified outcomes (e.g. in a published protocol), unclear risk to those studies that provided no information on this domain and high risk to studies that had evident inconsistencies between outcomes (e.g. between protocol and the trial publication). </p> </li> <li> <p>Other sources of bias, for example funding sources for the studies (checking for possible conflicts of interest raised by the funding). We assessed studies as being at low risk of bias (no notable concerns, e.g. funding by governmental institution), high risk of bias (notable concerns, e.g. funding by pharmaceutical company) or unclear risk of bias (funding source not disclosed). </p> </li> </ul> </p> <p>We assessed overall risk of bias according to the Cochrane Handbook (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD011108-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated the risk ratio (RR) and the corresponding 95% confidence intervals (CI) and P value for dichotomous outcomes. We calculated the mean difference (MD) and its corresponding 95% CI when means and standard deviations (SD) were available for continuous outcomes. If such information was unavailable, we planned to use the methods described in Chapter 16 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to calculate standardised mean differences (SMD) from, for example, F ratios, t values, Chi<sup>2</sup> values and correlation coefficients (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). In cases where continuous measures were used to assess the same outcomes using different scales, we planned to pool these data using Hedges' g to estimate the SMD if such information was unavailable. We planned to report study‐level effects narratively when effect sizes could not be pooled. We would also have calculated numbers needed to treat for an additional beneficial outcome (NNTB) and additional harmful outcomes (NNTH). </p> <p>We narratively described the data for continuous outcomes that were skewed. We defined skewed data according to Section 10.5.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD011108-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We only included studies that randomised the individual participant. For cross‐over trials, one major concern is carry‐over effect, which occurs when an effect of the treatment in the first phase is carried over to the second phase. We only used data from the first phase of cross‐over studies to avoid the carry‐over effect. </p> </section> <section id="CD011108-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We assessed missing data in the included studies. Where possible, we investigated and reported the reasons and numbers of those dropping out of each included study. Where studies had missing data, we initially attempted to contact the study authors to obtain this information. We performed an ITT analysis for dichotomous outcomes. If there was missing participant information, we recorded this and commented in the individual study's risk of bias table. We assigned participants with missing data to a 'zero improvement' category, and we performed a sensitivity analysis comparing the resulting effect sizes with those obtained using completer‐only data. We intended to use BOCF, where rating scales were employed for continuous outcomes. However, this was not done as data of the few continuous outcomes were skewed. </p> </section> <section id="CD011108-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We intended to assess for heterogeneity among primary outcome studies using the I<sup>2</sup> statistic along with its corresponding P and Chi<sup>2</sup> values (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>), and discuss any observed heterogeneity and its magnitude. We used a P value of 0.10 to determine statistical significance of heterogeneity according to the <i>Cochrane Handbook for Systematic Reviews of Interventions </i> (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). We planned to investigate possible sources using subgroup analyses and sensitivity analyses had we identified important heterogeneity (I<sup>2</sup> greater than 50%). </p> </section> <section id="CD011108-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched for the original trial protocols of the included studies and compared the results with these when were possible. We compared the reported outcomes against the methods section of the paper to look for selective reporting of outcomes when no protocol was available. </p> </section> <section id="CD011108-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We entered all extracted data into Review Manager 5 software for analysis (<a href="./references#CD011108-bbs2-0063" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). In order to take into account differences between studies, we synthesised data using a random‐effects model. We used a fixed‐effect model in a sensitivity analysis in order to investigate any differences in the estimate of effect. We meta‐analysed the data where possible. Where this was not feasible, we summarised data narratively in the results and discussion sections and the relevant tables. </p> </section> <section id="CD011108-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses had there been data available:</p> <p> <ul id="CD011108-list-0005"> <li> <p>method of administration (long‐acting versus short‐acting);</p> </li> <li> <p>single dose versus multiple dose;</p> </li> <li> <p>type of cancer;</p> </li> <li> <p>age (adults versus children).</p> </li> </ul> </p> </section> <section id="CD011108-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to examine the robustness of meta‐analyses by conducting the following sensitivity analysis had there been sufficient data available: </p> <p> <ul id="CD011108-list-0006"> <li> <p>exclude studies at 'high risk of bias' across any one of the risk of bias domains in order to assess any differences in the estimate of treatment effect; </p> </li> <li> <p>for high levels of attrition (greater than 10%) in individual studies, comparing completer‐only data with our assumptions of ITT; </p> </li> <li> <p>to assess any differences when synthesising data using a fixed‐effect rather than a random‐effects model. </p> </li> </ul> </p> </section> <section id="CD011108-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD011108-sec-0039"> <h5 class="title">Assessment of the certainty of the evidence</h5> <p>We assessed the overall certainty of the evidence for each outcome using GRADE (<a href="./references#CD011108-bbs2-0039" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>), and presented it in summary of findings tables to present the main findings of a review in a transparent and simple tabular format. </p> <p>The GRADE system uses the following criteria for assigning grade of evidence.</p> <p> <ul id="CD011108-list-0007"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>The GRADE system uses the following five domains to assess the certainty of evidence.</p> <p> <ul id="CD011108-list-0008"> <li> <p>Study limitations (risk of bias): refer to limitations in the study design, which would be assessed according to Cochrane risk of bias assessment (<a href="./references#CD011108-bbs2-0043" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions 6.0 (updated August 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </li> <li> <p>Inconsistency of results: refers to unexplained heterogeneity of results.</p> </li> <li> <p>Indirectness of evidence: refers to the uncertainty about directness.</p> </li> <li> <p>Imprecision: refers to uncertainty about the results.</p> </li> <li> <p>Publication bias: refers to a systematic underestimation or an overestimation of the underlying beneficial or harmful effect due to the selective publication of studies. </p> </li> </ul> </p> <p>We downgraded the certainty of evidence if there was:</p> <p> <ul id="CD011108-list-0009"> <li> <p>risk of bias: serious (−1) or very serious (−2) limitation to study certainty;</p> </li> <li> <p>inconsistency: important unexplained heterogeneity (−1);</p> </li> <li> <p>indirectness: some (−1) or major (−2) uncertainty about directness;</p> </li> <li> <p>imprecision: imprecise or sparse data (−1);</p> </li> <li> <p>publication bias: high probability of reporting bias (−1).</p> </li> </ul> </p> </section> <section id="CD011108-sec-0040"> <h5 class="title">Summary of findings table</h5> <p>We included three summary of findings tables, one comparing hydromorphone versus oxycodone, one comparing hydromorphone versus morphine and one comparing hydromorphone versus fentanyl. Had we identified any studies comparing hydromorphone versus placebo we planned to produce a summary of findings table for the comparison. We included key information concerning the certainty of evidence, the magnitude of effect of the interventions examined and the sum of available data on the outcomes: </p> <p> <ul id="CD011108-list-0010"> <li> <p>participant‐reported pain intensity;</p> </li> <li> <p>participant‐reported pain relief;</p> </li> <li> <p>specific adverse events: nausea, vomiting, dizziness, constipation</p> </li> <li> <p>quality of life.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011108-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011108-sec-0041"></div> <section id="CD011108-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD011108-sec-0043"> <h4 class="title">Results of the search</h4> <p>Details of the search results are illustrated in the PRISMA table (<a href="#CD011108-fig-0001">Figure 1</a>). </p> <p>The searches of the three databases retrieved 156 records. Our screening of the reference lists of included publications revealed 17 additional records. There were 151 records after deduplication. We excluded 133 records based on titles and abstracts. We obtained the full text of the remaining 18 records. We excluded two studies (<a href="./references#CD011108-bbs2-0009" title="AmsbaughAK , AmsbaughMJ , El-GhamryMN , DerhakeBM . Optimal epidural analgesia for patients diagnosed as having gynecologic cancer undergoing interstitial brachytherapy. Journal of Clinical Anesthesia2016;35:509-15. ">Amsbaugh 2016</a>; <a href="./references#CD011108-bbs2-0014" title="YangYQ , WuJP , LiHL , YeSJ , XuXY , ChengL , et al. Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on Open Access mood, opioid adverse effects, and recovery. BMC Anesthesiology2018;18(37):1-10. ">Yang 2018</a>) (see <a href="./references#CD011108-sec-0124" title="">Characteristics of excluded studies</a> table). We added eight records to the <a href="./references#CD011108-sec-0125" title="">Characteristics of studies awaiting classification</a> table due to the lack of access to full text (<a href="./references#CD011108-bbs2-0015" title="ACTRN12605000696695. Double-blind, double-dummy, randomised, parallel-arm equivalence [non-inferiority] study comparing hydromorphone hydrochloride extended-release [HHER] capsules to MS Contin tablets, dosed at a ratio of 1:7.5 to relieve pain, in cancer or non-cancer patients with a history of moderate to severe pain. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=682 (first received 13 September 2005). ">ACTRN12605000696695</a>; <a href="./references#CD011108-bbs2-0018" title="ChiCTR-IPR-17013446. A multicenter clinical trial of hydromorphone hydrochloride in the treatment of cancer breakthrough pain. http://www.chictr.org.cn/showproj.aspx?proj=22941 (first received 19 November 2017). ">ChiCTR‐IPR‐17013446</a>; <a href="./references#CD011108-bbs2-0016" title="ChiCTR1900028015. A multicenter, randomized, parallel, controlled clinical study of patient controlled intravenous analgesia with hydromorphone hydrochloride injection and morphine hydrochloride injection for moderate to severe cancer. http://www.chictr.org.cn/hvshowproject.aspx?id=20839 (first received 8 December 2005). ">ChiCTR1900028015</a>; <a href="./references#CD011108-bbs2-0017" title="ChiCTR2000037845. A multicenter clinical trial of hydromorphone PCA versus oxycodone oral titration in the treatment of cancer pain. http://www.chictr.org.cn/com/25/hvshowproject.aspx?id=63054 (first received 8 November 2020). ">ChiCTR2000037845</a>; <a href="./references#CD011108-bbs2-0019" title="CTRI/2009/091/000244. A multicenter, multinational, randomized, open-label, parallel-group trial to evaluate the safety of fentanyl TAIFUN; treatment after titrated dose administration and the current breakthrough pain treatment for breakthrough pain in cancer patients on maintenance opioid therapy. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=493&amp;EncHid=&amp;modid=&amp;compid=%27,%27493det%27 (first received 24 June 2009). ">CTRI/2009/091/000244</a>; <a href="./references#CD011108-bbs2-0020" title="EUCTR2004-005187-24-SK. Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain requiring continuous opioid therapy. https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005187-24/SK (first received 30 January 2006). ">EUCTR2004‐005187‐24‐SK</a>; <a href="./references#CD011108-bbs2-0021" title="EUCTR2008-002273-12-IT. Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors. https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002273-12/IT (first received 21 May 2008). ">EUCTR2008‐002273‐12‐IT</a>; <a href="./references#CD011108-bbs2-0022" title="JPRN-JapicCTI-142666. DS-7113b extended-release tablet phase III study. https://rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-142666 (first received 1st October 2014). ">JPRN‐JapicCTI‐142666</a>). We identified three new ongoing studies (<a href="./references#CD011108-bbs2-0024" title="NCT02084355. Study of opioid rotation versus opioid escalation in patients with moderate to severe cancer pain [Efficacy and safety of opioid rotation compared with opioid dose escalation in patients with moderate to severe cancer pain – open label, randomized, prospective study]. clinicaltrials.gov/ct2/show/NCT02084355 (first received 5 March 2014). ">NCT02084355</a>; <a href="./references#CD011108-bbs2-0025" title="NCT04243954. Intravenous vs oral analgesia in cancer patients with severe pain after successful titration. clinicaltrials.gov/ct2/show/NCT04243954 (first posted 28 January 2020). ">NCT04243954</a>; <a href="./references#CD011108-bbs2-0026" title="NCT04296305. Effect of opioid infusion rate on abuse liability potential of intravenous hydromorphone for cancer pain. clinicaltrials.gov/ct2/show/NCT04296305 (first received 5 March 2020). ">NCT04296305</a>). We included four new studies (five references) in this update that were reported in four references (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). For a further description of our screening process, see the study flow diagram (<a href="#CD011108-fig-0001">Figure 1</a>). </p> </section> <section id="CD011108-sec-0044"> <h4 class="title">Included studies</h4> <p>We found eight RCTs including adults (1283 participants, with data for 1181 participants available for analysis) that satisfied the inclusion criteria of this review; four included in the previous version of the review (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>), and four new studies (five references) for this update (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>); see <a href="./references#CD011108-sec-0123" title="">Characteristics of included studies</a> table for a full description. We contacted the authors regarding the uncertainty of the uniqueness of <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>, and received confirmation in their response that these were two separate studies. We found no studies that included children or studies that compared hydromorphone with placebo. </p> <section id="CD011108-sec-0045"> <h5 class="title">Design and setting</h5> <p>Six included studies were conducted in high‐income countries. <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> was conducted in Canada; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> was a multi‐centre trial involving 37 centres in Belgium, Canada, France, Germany, the Netherlands, Spain, Sweden and the UK. This study reported that it included inpatients, outpatients and day patients. <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> was conducted in the UK. <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> were conducted in Japan. <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> was conducted in the US. The remaining two studies were conducted in China (<a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). </p> <p>Two studies had a cross‐over study design (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>), and four had a parallel study design (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). The other two had a two‐stage, parallel design that included an initial titration stage followed by a slow release (SR) or maintenance phase (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). </p> </section> <section id="CD011108-sec-0046"> <h5 class="title">Sample sizes</h5> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> was the smallest trial of the eight with 44 randomised participants, but only 31 people completed the trial. <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> had a sample size of 200. <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> randomised 100 participants, but only 89 completed the trial. <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> randomised 260 participants, but only 137 completed the trial through to the end of maintenance phase. <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> randomised 181 participants but only 147 completed the trial. <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> also randomised 181 participants, but only 160 completed the trial. <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> randomised 84 participants and 82 completed the trial. <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> randomised 233 participants, and all the participants received the intervention as assigned. However, 211 participants dropped out due to various reasons during the three‐month follow‐up. </p> </section> <section id="CD011108-sec-0047"> <h5 class="title">Participants</h5> <p>All eight studies included adults with cancer pain. The mean age in Hagen 1997, Hanna 2008, and Yu 2014 was 53 to 59 years with evenly distributed gender; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> included people over 18 years but no age range was given. <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> required participants to be aged over 20 years, but no age range was given. The proportion of men in the studies ranged from 42% (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>) to 67.4% (<a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>). <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> included participants who were 22 to 84 years old, and <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> included participants who were 18 to 80 years old. Both studies included participants with evenly distributed gender. We found no studies including children. None of the studies stated the cancer stage. </p> <p>The severity of cancer pain was unclear in <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>, but participants were on a stable dose of analgesics (active controlled‐release). Participants in <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> had moderate to severe pain and required 60 mg to 540 mg of oral morphine every 24 hours at baseline. <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> and <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> involved people with moderate to severe cancer pain. The locations of the primary tumour were mainly breast, colorectal, lung, prostate, gastrointestinal and central nervous system. A smaller proportion of participants had cancer in the oral cavity, lymphoma, leukaemia and bone cancer. <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> involved people with moderate to severe cancer pain. The locations of the primary tumour were mainly lung, gastrointestinal and hepatic‐biliary pancreatic. A smaller proportion of participants had cancer of the urogenital system, head/neck and breast. <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> included people with severe cancer pain and who had been on opioid therapy for one week or longer. <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> included people with moderate to severe cancer pain. </p> </section> <section id="CD011108-sec-0048"> <h5 class="title">Interventions and comparators</h5> <p>Interventions included hydromorphone compared with oxycodone (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>), hydromorphone compared with morphine (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>), and hydromorphone compared with fentanyl (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>). </p> <section id="CD011108-sec-0049"> <h6 class="title">Hydromorphone compared with oxycodone</h6> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> compared controlled release (CR) hydromorphone versus CR oxycodone given every 12 hours for seven days. The mean daily doses were 24 (SD 4) mg for hydromorphone and 120 (SD 22) mg for oxycodone. Cross‐over was completed without a washout period and we only used pre‐crossover data. </p> <p><a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> compared ER hydromorphone versus ER oxycodone orally for seven days. The daily doses were 4 mg/day for hydromorphone and 10 mg/day for oxycodone. </p> <p><a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> compared hydromorphone tablet with oxycodone powder given four times a day for five days. The daily doses were 4 mg/day for hydromorphone and 10 mg/day for oxycodone. </p> <p>In the two‐stage <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> trial, the eight‐day titration phase was followed by a 28‐day maintenance phase. Both phases used CR formulations; OROS hydromorphone or oxycodone CR and the maximum daily doses were 32 mg for OROS hydromorphone and 80 mg for oxycodone CR. </p> </section> <section id="CD011108-sec-0050"> <h6 class="title">Hydromorphone compared with morphine</h6> <p>The titration stage for <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> used instant release (IR) formulations of either hydromorphone or morphine given every four hours (six times daily) for two to nine days. The titrated dosage of hydromorphone during this phase was 12 mg/day to 108 mg/day and for morphine was 62 mg/day to 540 mg/day. This was followed by a 10‐ to 15‐day SR stage, when the same drugs were given but in a CR formulation; OROS hydromorphone once daily or morphine CR twice daily. The starting dose was the same level as dose‐stable pain achieved in IR phase, adjusted as required every two days at most. </p> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> used intrathecal hydromorphone with a mean starting daily infusion dose of 0.276 (SD 0.53) mg and intrathecal morphine with a mean starting daily infusion dose of 1.551 (SD 4.20) mg. </p> <p><a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> used tablet formulation of hydromorphone CR 4 mg and morphine CR 30 mg. </p> </section> <section id="CD011108-sec-0051"> <h6 class="title">Hydromorphone compared with fentanyl</h6> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> used intravenous hydromorphone 1.5 mg at time of initiation and allowed a rescue dose at time of 0.5 hour, and nasal spray fentanyl 100 μg at time of initiation and allowed a rescue dose at time of 0.5 hour. </p> </section> </section> <section id="CD011108-sec-0052"> <h5 class="title">Outcomes</h5> <p>We were able to collect data on participant‐reported pain intensity, but the data were skewed. Other outcomes reported by the studies included adverse events, leaving the study early and death. </p> </section> <section id="CD011108-sec-0053"> <h5 class="title">Funding sources</h5> <p>Pharmaceutical companies funded six included studies, including Purdue Pharma (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>), Johnson &amp; Johnson (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>), Daiichi Sankyo co Ltd (<a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>), Napp Laboratories Ltd (<a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>), and Assertio, Inc. (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>). One study reported their funding sources from a non‐commercial organisation, the Science and Technology Commission of Shanghai Municipality (<a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). One study did not report their funding sources (<a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). </p> </section> </section> <section id="CD011108-sec-0054"> <h4 class="title">Excluded studies</h4> <p>We excluded six studies. <a href="./references#CD011108-bbs2-0014" title="YangYQ , WuJP , LiHL , YeSJ , XuXY , ChengL , et al. Prospective investigation of intravenous patient-controlled analgesia with hydromorphone or sufentanil: impact on Open Access mood, opioid adverse effects, and recovery. BMC Anesthesiology2018;18(37):1-10. ">Yang 2018</a> was an RCT and had relevant interventions, but included adults with acute postoperative pain after cancer surgery. The remaining five studies had relevant participants and interventions, but they were not RCTs (<a href="./references#CD011108-bbs2-0009" title="AmsbaughAK , AmsbaughMJ , El-GhamryMN , DerhakeBM . Optimal epidural analgesia for patients diagnosed as having gynecologic cancer undergoing interstitial brachytherapy. Journal of Clinical Anesthesia2016;35:509-15. ">Amsbaugh 2016</a>; <a href="./references#CD011108-bbs2-0010" title="HanHS , LeeKH , LeeKH , RyuJS , KimYC , ParkSW , et al. A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics. Supportive Care in Cancer2014;22(3):741-50. [PMID: 24203087]">Han 2014</a>; <a href="./references#CD011108-bbs2-0011" title="LeeKH , KimMK , HyunMS , KimJY , ParkKU , SongHS , et al. Clinical effectiveness and safety of OROS hydromorphone in breakthrough cancer pain treatment: a multicenter, prospective, open-label study in Korean patients. Journal of Opioid Management2012;8(4):243-52. ">Lee 2012</a>; <a href="./references#CD011108-bbs2-0012" title="WirzS , WartenbergHC , NadstawekJ . Less nausea, emesis, and constipation comparing hydromorphone and morphine? A prospective open-labeled investigation on cancer pain. Supportive Care Cancer2008;16(9):999-1009. ">Wirz 2008</a>; <a href="./references#CD011108-bbs2-0013" title="WirzS , WittmannM , SchenkM , SchroeckA , SchaeferN , MuellerM , et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. European Journal of Pain2009;13(7):737-43. ">Wirz 2009</a>). See <a href="./references#CD011108-sec-0124" title="">Characteristics of excluded studies</a> table for further details. </p> </section> <section id="CD011108-sec-0055"> <h4 class="title">Studies awaiting classification</h4> <p>Eight studies are awaiting classification due to the lack of access to the full text (<a href="./references#CD011108-bbs2-0015" title="ACTRN12605000696695. Double-blind, double-dummy, randomised, parallel-arm equivalence [non-inferiority] study comparing hydromorphone hydrochloride extended-release [HHER] capsules to MS Contin tablets, dosed at a ratio of 1:7.5 to relieve pain, in cancer or non-cancer patients with a history of moderate to severe pain. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=682 (first received 13 September 2005). ">ACTRN12605000696695</a>; <a href="./references#CD011108-bbs2-0018" title="ChiCTR-IPR-17013446. A multicenter clinical trial of hydromorphone hydrochloride in the treatment of cancer breakthrough pain. http://www.chictr.org.cn/showproj.aspx?proj=22941 (first received 19 November 2017). ">ChiCTR‐IPR‐17013446</a>; <a href="./references#CD011108-bbs2-0016" title="ChiCTR1900028015. A multicenter, randomized, parallel, controlled clinical study of patient controlled intravenous analgesia with hydromorphone hydrochloride injection and morphine hydrochloride injection for moderate to severe cancer. http://www.chictr.org.cn/hvshowproject.aspx?id=20839 (first received 8 December 2005). ">ChiCTR1900028015</a>; <a href="./references#CD011108-bbs2-0017" title="ChiCTR2000037845. A multicenter clinical trial of hydromorphone PCA versus oxycodone oral titration in the treatment of cancer pain. http://www.chictr.org.cn/com/25/hvshowproject.aspx?id=63054 (first received 8 November 2020). ">ChiCTR2000037845</a>; <a href="./references#CD011108-bbs2-0019" title="CTRI/2009/091/000244. A multicenter, multinational, randomized, open-label, parallel-group trial to evaluate the safety of fentanyl TAIFUN; treatment after titrated dose administration and the current breakthrough pain treatment for breakthrough pain in cancer patients on maintenance opioid therapy. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=493&amp;EncHid=&amp;modid=&amp;compid=%27,%27493det%27 (first received 24 June 2009). ">CTRI/2009/091/000244</a>; <a href="./references#CD011108-bbs2-0020" title="EUCTR2004-005187-24-SK. Randomized, open label, comparative parallel group study to assess efficacy and safety of flexible dosages of OROS hydromorphone once-daily compared to sustained release oxycodone twice-daily in subjects with chronic non-malignant pain requiring continuous opioid therapy. https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-005187-24/SK (first received 30 January 2006). ">EUCTR2004‐005187‐24‐SK</a>; <a href="./references#CD011108-bbs2-0021" title="EUCTR2008-002273-12-IT. Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors. https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-002273-12/IT (first received 21 May 2008). ">EUCTR2008‐002273‐12‐IT</a>; <a href="./references#CD011108-bbs2-0022" title="JPRN-JapicCTI-142666. DS-7113b extended-release tablet phase III study. https://rctportal.niph.go.jp/en/detail?trial_id=JapicCTI-142666 (first received 1st October 2014). ">JPRN‐JapicCTI‐142666</a>). See <a href="./references#CD011108-sec-0125" title="">Characteristics of studies awaiting classification</a> table for further details. </p> </section> <section id="CD011108-sec-0056"> <h4 class="title">Ongoing studies</h4> <p>We found four ongoing RCTs eligible for inclusion. One compared hydromorphone with placebo in adults with moderate to severe cancer pain with unclear total sample size and the status is recruiting (<a href="./references#CD011108-bbs2-0026" title="NCT04296305. Effect of opioid infusion rate on abuse liability potential of intravenous hydromorphone for cancer pain. clinicaltrials.gov/ct2/show/NCT04296305 (first received 5 March 2020). ">NCT04296305</a>). One compared hydromorphone with oxycodone and fentanyl patch in adults with moderate to severe cancer pain with unclear total sample size and January 2016 as the expected completion date (<a href="./references#CD011108-bbs2-0024" title="NCT02084355. Study of opioid rotation versus opioid escalation in patients with moderate to severe cancer pain [Efficacy and safety of opioid rotation compared with opioid dose escalation in patients with moderate to severe cancer pain – open label, randomized, prospective study]. clinicaltrials.gov/ct2/show/NCT02084355 (first received 5 March 2014). ">NCT02084355</a>). One compared intravenous hydromorphone with oral morphine in 95 adults with moderate to severe pain (<a href="./references#CD011108-bbs2-0025" title="NCT04243954. Intravenous vs oral analgesia in cancer patients with severe pain after successful titration. clinicaltrials.gov/ct2/show/NCT04243954 (first posted 28 January 2020). ">NCT04243954</a>). The study is completed but not published yet. We found no reports relating to this study in our latest searches. One compared fentanyl and other opioids (which includes hydromorphone and oxycodone), in adults with moderate to severe cancer pain, with 500 as the total expected sample size and January 2010 as the expected completion date (<a href="./references#CD011108-bbs2-0023" title="NCT00822614. The safety of fentanyl TAIFUN treatment after titrated dose administration and the current breakthrough pain treatment for breakthrough pain in cancer patients. clinicaltrials.gov/ct2/show/NCT00822614 (first received 14 January 2009). ">NCT00822614</a>). </p> </section> </section> <section id="CD011108-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD011108-fig-0002">Figure 2</a> and <a href="#CD011108-fig-0003">Figure 3</a> for graphic representation of the risk of bias assessment. </p> <div class="figure" id="CD011108-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011108-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD011108-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011108-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD011108-sec-0058"> <h4 class="title">Allocation</h4> <section id="CD011108-sec-0059"> <h5 class="title">Random sequence generation</h5> <p>We assigned five studies at low risk of bias for random sequence generation (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>), and three at unclear risk of bias (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>). </p> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> randomised participants on a 1:1 ratio via a central computer‐generated randomisation list. Similarly, <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> used central randomisation (1:1) using an online dynamic minimisation allocation program. <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> employed a third‐party randomisation method. <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> used a block random coding table for randomisation. </p> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>, <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>, and <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> did not describe randomisation procedure in detail. </p> </section> <section id="CD011108-sec-0060"> <h5 class="title">Allocation concealment</h5> <p>None of the studies provided explicit detail on allocation concealment. We considered <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>, <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>, and <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> as more likely to have used concealment since the randomisation was performed via a central list or block random coding table, and so we judged these studies at low risk of bias. We also judged <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> and <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> at low risk of bias because they used third‐party randomisation, which typically conceals allocation. </p> <p>We judged <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>, <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>, and <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> at unclear risk of bias because there were no details in the papers, thus we were unable to make any conclusive judgement. </p> </section> </section> <section id="CD011108-sec-0061"> <h4 class="title">Blinding</h4> <section id="CD011108-sec-0062"> <h5 class="title">Blinding of participants and personnel</h5> <p>Six studies were described as double‐blind, however <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> did not provide further description of the blinding method; in this case, we accepted the author's reporting as true and accurate, and thus rated it at low risk of bias. <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>, <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>, <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>, and <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> used double‐blind and double‐dummy methods to protect the blinding. <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> did not offer an explicit description on blinding; however, we considered that double‐blinding was likely to have been used, as the study employed over‐encapsulated tablet and placebo to mask treatment, hence, we rated it at low risk of bias. <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> was reported as single blind with participants and investigators being blinded, hence, we rated it at low risk of bias. <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> was stated as an open‐label design, hence, we rated it at high risk of bias. </p> </section> <section id="CD011108-sec-0063"> <h5 class="title">Blinding of outcome assessment</h5> <p>It was unclear if the outcome assessment was blinded in any of the studies; however, as most of the outcomes were participant‐reported, we rated this item at low risk of bias across all included studies. </p> </section> </section> <section id="CD011108-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>Dropout was common and the proportion of dropout exceeded 10% in five studies (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> had applied ITT analysis and the reasons and proportion for dropout was similar between groups, however, the dropout rate was greater than 10%, thus we rated it at high risk. We rated <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> at high risk as it had over 10% dropout and these were excluded from final analysis, which further compromised the already weakened evidence. Sixty (46%) people dropped out of the hydromorphone group and 63 (48%) people dropped out of the oxycodone group in <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>, but the proportion and reasons were balanced between groups. Nevertheless, we judged it at high risk because the dropout rate was greater than 10%. <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> reported that all participants received the intervention and 211 (90%) dropped out during the three‐month follow‐up period with reasons given and were included in the final analysis. Hence, we judged this study at high risk. </p> <p><a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> had 11 (11%) participants drop out with reasons given and were included in the final analysis. The dropout rate was over 10%, but only marginally so. We considered the dropout was unlikely to have caused significant bias, as reasons and proportion of dropout were comparable between groups. Therefore, we judged this study at low risk of bias for this domain. The proportion of dropout was less than 10% in <a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>, <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>, and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>, thus we judged them at low risk. </p> </section> <section id="CD011108-sec-0065"> <h4 class="title">Selective reporting</h4> <p>Three trials had protocols, and we identified no differences between the planned outcome measures in the protocol and the reported outcome measures in the full report (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). Two trials had no available protocols, but when we compared the reported outcomes with the papers' methodology section we found no evidence of selective reporting (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). Therefore, we judged these five included studies at low risk of reporting bias. The other two trials also had no available protocols (<a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>), but when we compared the reported outcomes with the papers' methodology sections we found both studies had non‐reported planned outcomes. However, as the non‐reported outcomes were not relevant to this review, we judged both studies at low risk of reporting bias. </p> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> had a protocol and we identified that the predefined quality of life outcome was not reported in the published report, hence, we judged this study at high risk for this domain. </p> </section> <section id="CD011108-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>We judged seven studies at high risk of other bias as they were funded by pharmaceutical companies (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). We judged <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> at unclear risk for this domain because the sponsorship of this study was not commercial (the Science and Technology Commission of Shanghai Municipality). However, the first author of this study was the person who reported grants, which may have led to a conflict of interest. Hence, we judged it at unclear risk for this domain. </p> </section> </section> <section id="CD011108-sec-0067"> <h3 class="title" id="CD011108-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD011108-tbl-0001"><b>Summary of findings 1</b> Hydromorphone compared with oxycodone for people with moderate to severe cancer pain</a>; <a href="./full#CD011108-tbl-0002"><b>Summary of findings 2</b> Hydromorphone compared with morphine for people with moderate to severe cancer pain</a>; <a href="./full#CD011108-tbl-0003"><b>Summary of findings 3</b> Hydromorphone compared with fentanyl for people with moderate to severe cancer pain</a> </p> <p>We were able to extract numerical data from seven of the eight included studies (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> reported the outcomes with P values only. </p> <section id="CD011108-sec-0068"> <h4 class="title">Comparison 1: hydromorphone compared with placebo</h4> <p>We identified no studies comparing hydromorphone with placebo.</p> </section> <section id="CD011108-sec-0069"> <h4 class="title">Comparison 2: hydromorphone compared with oxycodone</h4> <p>Four studies compared hydromorphone with oxycodone, including data from <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> (n = 44), <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> (n = 181), <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> (n = 181), and <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> (n = 260). </p> <section id="CD011108-sec-0070"> <h5 class="title">2.1 Participant‐reported pain intensity</h5> <p>Three studies reported participant‐reported pain intensity using VAS scores (0 to 100 with a higher score indicating a worse outcome) (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>). We presented data in separate tables because they were skewed. </p> <p>In <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>, the mean VAS (high score = poor outcome) endpoint pain intensity scores at seven days of treatment were similar between groups (mean: hydromorphone 28.86 (SD 17.08), n = 19; oxycodone 30.30 (SD 25.33), n = 12; <a href="./references#CD011108-fig-0004" title="">Analysis 1.1</a>). Although according to the predefined threshold in the protocol (i.e. 30/100 mm on VAS), it was clear that the hydromorphone group achieved 'no worse than mild pain' and the oxycodone group did not achieve 'no worse than mild pain', the result needed careful interpretation because the data were skewed. Both groups achieved 'no worse than mild pain' on the categorical pain intensity as measured on an ordinal scale (higher = worse outcome) (mean: hydromorphone 1.5 (standard deviation (SD) 0.4) points; oxycodone 1.4 (SD 0.3) points; <a href="#CD011108-tbl-0004">Table 1</a>). </p> <div class="table" id="CD011108-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison 2: hydromorphone versus oxycodone (pain intensity and adverse events from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Oxycodone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>MD (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorical pain intensity (ordinal scale) – at 7 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (−0.15 to 0.35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPI (changed data) – at 28 days of maintenance therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.10 (−1.67 to 1.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific adverse events – nausea – at 7 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.63 (−15.13 to 13.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific adverse events – sedation – at 7 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−4.89 (−22.15 to 12.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPI: Brief Pain Inventory; CI: confidence interval; MD: mean difference; n: number of participants; SD: standard deviation. </p> </div> </div> <p>In <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>, the mean VAS endpoint pain intensity scores at seven days of treatment were similar between groups (mean: hydromorphone 23 (SD 17.91), n = 86; oxycodone 23.2 (SD 18.83), n = 92). The result reported by <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> was consistent with <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> and <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> (hydromorphone 24.7 (SD 22.11), n = 88; oxycodone 27.9 (SD 21.05), n = 84). </p> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> reported BPI score (0 to 10 with a higher score indicating a worse outcome). The BPI change score of 'pain at its worst in the past 24 hours' from baseline was similar between groups at 28 days of maintenance therapy (mean: hydromorphone –1.8 (SD 3.29), n = 40; oxycodone –1.7 (SD 3.91), n = 41; <a href="#CD011108-tbl-0004">Table 1</a>). The study reported only the mean BPI score for 'mean pain in the past 24 hours' (mean: hydromorphone 2.9; oxycodone 3.3, SDs not reported, n = 81). </p> <p>None of the included studies reported number of participants who achieved 'no worse than mild pain'. </p> <p>We rated the certainty of the evidence for participant‐reported pain intensity as very low, downgrading twice for very serious study limitations and once for serious imprecision (<a href="./full#CD011108-tbl-0001">summary of findings Table 1</a>). We decided not to downgrade for suspected publication bias as the outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </section> <section id="CD011108-sec-0071"> <h5 class="title">2.2 Participant‐reported pain relief</h5> <p>No studies reported participant‐reported pain relief.</p> </section> <section id="CD011108-sec-0072"> <h5 class="title">2.3 Specific adverse events</h5> <p>Four studies reported specific adverse events (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). </p> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> presented data using VAS at seven days of treatment in separate data tables because the continuous data for this outcome were skewed (<a href="#CD011108-tbl-0004">Table 1</a>). The mean endpoint nausea scores were comparable between groups (hydromorphone 16.05 (SD 17.51), n = 19; oxycodone 16.68 (SD 21.53), n = 12); there was no clear evidence of a difference (mean difference ‐4.89, 95% CI ‐22.15 to 12.37; <a href="#CD011108-tbl-0004">Table 1</a>). </p> <p>The above findings were consistent with <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>, <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>, and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>, which indicated no clear evidence of a difference between groups at the end of treatment (ranged from five days of treatment to 28 days of maintenance therapy) for the following adverse events: nausea (RR 1.13, 95% CI 0.74, 1.73; n = 622); vomiting (RR 1.18, 95% CI 0.72 to 1.94; n = 622), dizziness (RR 0.91, 95% CI 0.58 to 1.44; n = 441) and constipation (RR 0.92, 95% CI 0.72 to 1.19; n = 622) (<a href="./references#CD011108-fig-0005" title="">Analysis 1.2</a>). There was no clear evidence of a difference between groups for other adverse events (<a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). For single‐study reported adverse events, see <a href="#CD011108-tbl-0005">Table 2</a>. </p> <div class="table" id="CD011108-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparison 2: hydromorphone versus oxycodone (adverse events and deaths from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Oxycodone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>RR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>RR</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Specific adverse events</b> – end of treatment (<b>ranged from 5 days of treatment to 28 days</b> <b>of maintenance therapy)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.21 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal distension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.35 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.47 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.48 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bone marrow failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.39 to 1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.48 to 2.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delirium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.22 to 1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.43 to 3.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.15 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.12 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.41 to 2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema peripheral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.59 to 2.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.40 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.53 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.45 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.21 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White blood cell count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.39 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Death</b> – at 28 days of maintenance therapy </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 (0.22 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; n: number; RR: risk ratio.</p> </div> </div> <p>We rated the certainty of the evidence for specific adverse events as very low, downgrading the outcomes of nausea, vomiting, dizziness and constipation twice for very serious study limitations and once for serious imprecision. We decided not to downgrade for inconsistency and publication bias as the outcomes had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate (<a href="./full#CD011108-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD011108-sec-0073"> <h5 class="title">2.4 Serious adverse events</h5> <p>Three studies involving 606 participants reported the incidence of serious adverse events (<a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). We found no evidence of a difference between hydromorphone and oxycodone (RR 0.62, 95% CI 0.39 to 1.00; <a href="./references#CD011108-fig-0006" title="">Analysis 1.3</a>). We rated the certainty of the evidence as very low, downgrading twice for very serious study limitations and once for serious imprecision. </p> </section> <section id="CD011108-sec-0074"> <h5 class="title">2.5 Quality of life</h5> <p>None of the studies reported quality of life.</p> </section> <section id="CD011108-sec-0075"> <h5 class="title">2.6 Leaving the study early</h5> <p>Four studies involving 666 participants reported participants leaving the study early between five days to 28 days of maintenance (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). We found no evidence of a difference between hydromorphone and oxycodone (RR 0.78, 95% CI 0.44 to 1.38; <a href="./references#CD011108-fig-0007" title="">Analysis 1.4</a>). We rated the certainty of the evidence as very low, downgrading twice for very serious study limitations (high risk of other bias and incomplete data) and imprecision. </p> </section> <section id="CD011108-sec-0076"> <h5 class="title">2.7 Death</h5> <p>One study involving 260 participants reported death within 28 days of maintenance therapy (<a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). This was claimed to be a consequence of disease progression, and there was no clear evidence of a difference between groups (RR 0.50, 95% CI 0.22 to 1.13; <a href="#CD011108-tbl-0005">Table 2</a>). <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> reported deaths at five days of treatment and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> at seven days of treatment. However, they did not provide a specific number of deaths in each group. We rated the certainty of the evidence as very low, downgrading twice for very serious study limitations (high risk of other bias and incomplete data) and imprecision. </p> </section> <section id="CD011108-sec-0077"> <h5 class="title">Sensitivity analysis for hydromorphone compared with oxycodone</h5> <p>We were unable to conduct any sensitivity analyses for individual studies comparing hydromorphone with oxycodone. All studies had a 'high risk of bias on any domain.' In addition, only <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> and <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> reported larger dropout rates (greater than 10%). Because <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> was not included in a meta‐analysis, we performed a sensitivity analysis for adverse events reported by <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>. When we included dropouts in the analysis, results were consistent with the original analysis, that there was no clear evidence of a difference between the two groups on adverse events outcomes. </p> </section> </section> <section id="CD011108-sec-0078"> <h4 class="title">Comparison 3: hydromorphone compared with morphine</h4> <p>Three studies reported data comparing hydromorphone with morphine (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). </p> <section id="CD011108-sec-0079"> <h5 class="title">3.1 Participant‐reported pain intensity</h5> <p>Three studies reported participant‐reported pain intensity (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). </p> <p><a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> measured pain intensity (VAS) at three timepoints: before the morning dose, six hours after the morning dose and before the evening dose. The study reported that there was no clear evidence of a difference between groups at all time points (P = 0.68 before the morning dose, P = 0.90 six hours after the morning dose and P = 0.90 before the evening dose) (<a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). It also reported that both treatments controlled pain satisfactorily (VAS from 8.47 mm to 10.43 mm), which indicated that participants in both groups achieved no worse than mild pain (less than 30 mm on the 0‐ to 100‐mm VAS) (<a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). </p> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> derived subscale data using the BPI scale measured at 24 days of treatment and found that the morphine group appeared to have a higher endpoint mean score on 'worst pain' (mean: hydromorphone 3.5 (SD 2.9), n = 99; morphine 4.3 (SD 3.0), n = 101; <a href="#CD011108-tbl-0006">Table 3</a>), nevertheless, mean scores on 'least pain' and 'mean pain' were almost identical. The 'mean pain' subscale data showed that both groups achieved no worse than mild pain. </p> <div class="table" id="CD011108-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Comparison 3: hydromorphone versus morphine (participant‐reported pain intensity: Brief Pain Inventory endpoint and visual analogue scale score from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Morphine</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>MD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>MD</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>BPI – worst pain subscale score at 24 days of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80 (−1.62 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>BPI – least pain subscale score at 24 days of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.55 to 0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>BPI – mean pain at 24 days of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.63 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 1 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (−0.15 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 2 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (−0.36 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 3 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.14 (−0.47 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 4 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.04 (−0.35 to 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 5 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.23 (−0.54 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 6 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.16 (−0.48 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 7 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (−0.32 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 8 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (−0.25 to 0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 9 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (−0.32 to 0.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 10 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14 (−0.17 to 0.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 11 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.04 (−0.34 to 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 12 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.15 (−0.45 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BPI: Brief Pain Inventory; CI: confidence interval; MD: mean difference; n: number of participants; SD: standard deviation; VAS: visual analogue scale. </p> </div> </div> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> measured the categorical score on VAS from week one to week 12 of the treatment. The study reported that there was no clear evidence of a difference between groups at all time points (mean: week 1: hydromorphone 2.78 (SD 1.63), n = 121; morphine 2.56 (SD 1.20), n = 112; P = 0.245; week 2: hydromorphone 2.56 (SD 1.41), n = 121; morphine 2.58 (SD 1.21), n = 112; P = 0.908; week 3: hydromorphone 2.48 (SD 1.28), n = 121; morphine 2.62 (SD 1.24), n = 112; P = 0.388; week 4: hydromorphone 2.52 (SD 1.33), n = 121; morphine 2.56 (SD 1.10), n = 112; P = 0.794; week 5: hydromorphone 2.40 (SD 1.34), n = 121; morphine 2.63 (SD 1.13), n = 112; P = 0.165; week 6: hydromorphone 2.42 (SD 1.3), n = 121; morphine 2.57 (SD 1.22), n = 112); P = 0.350; week 7: hydromorphone 2.51 (SD 1.25), n = 121; morphine 2.53 (SD 1.07), n = 112; P = 0.881; week 8: hydromorphone 2.47 (SD 1.41), n = 121; morphine 2.40 (SD 1.00), n = 112; P = 0.692; week 9: hydromorphone 2.56 (SD 1.5), n = 121; morphine 2.54 (SD 1.11), n = 112; P = 0.909; week 10: hydromorphone 2.66 (SD 1.35), n = 121; morphine 2.52 (SD 1.06), n = 112; P = 0.382; week 11: hydromorphone 2.35 (SD 1.32), n = 121; morphine 2.39 (SD 1.06), n = 112); P = 0.815; week 12: hydromorphone 2.22 (SD 1.22), n = 121); morphine 2.37 (SD 1.03), n = 112; P = 0.344; <a href="#CD011108-tbl-0006">Table 3</a>). </p> <p>We found no studies reporting the number of participants who achieved 'no worse than mild pain'. </p> <p>We rated the certainty of the evidence for participant‐reported pain intensity as very low, downgrading twice for very serious study limitations and once for serious imprecision (<a href="./full#CD011108-tbl-0002">summary of findings Table 2</a>). We decided not to downgrade for publication bias as the outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </section> <section id="CD011108-sec-0080"> <h5 class="title">3.2 Participant‐reported pain relief</h5> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> reported the number of participants with pain relief rate of 50% or greater at the end of the three‐month follow‐up period. There was no clear evidence of a difference between groups at the end of the follow‐up period (RR 0.99, 95% CI 0.84 to 1.18; P = 0.962; <a href="#CD011108-tbl-0007">Table 4</a>). </p> <div class="table" id="CD011108-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison 3: hydromorphone versus morphine (pain relief rate 50% or greater, adverse events, leaving study early and death from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>RR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Participants improved at 84 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% of participants with pain relief rate ≥ 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.84 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Specific adverse event</b> –<b>measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.73 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="17" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22 (0.72 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.72 (0.99 to 2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.90 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (1.12 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.009<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.74 (1.02 to 2.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (0.71 to 1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.74 (1.02 to 2.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.76 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.87 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45 (0.86 to 2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.66 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema peripheral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.61 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.76 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (0.90 to 2.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.73 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.58 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Serious adverse event</b> –<b>measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.48 to 2.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Adverse event measured during 84 days follow‐up of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.42 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Leaving study early measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 (0.95 to 2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.39 (0.67 to 2.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.81 (0.92 to 8.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Leaving study early measured at 84 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.89 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.55 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.33 to 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to change to other therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.45 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.24 to 3.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Death measured at 84 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.80 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Death measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15 (0.01 to 2.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events‐treatment related occurred within 6 days of treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Counts of reported events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Treatment related</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Counts of reported events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Treatment related</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study ID</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal discomfort/pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p><a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TOTAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Statistically significant P value. </p> <p>CI: confidence interval; n: number; RR: risk ratio.</p> </div> </div> <p>We rated the certainty of the evidence for participant‐reported pain relief as very low, downgrading twice for very serious study limitations and once for serious imprecision (<a href="./full#CD011108-tbl-0002">summary of findings Table 2</a>). We decided not to downgrade for publication bias as the outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </section> <section id="CD011108-sec-0081"> <h5 class="title">3.3 Specific adverse events</h5> <p>Three studies reported specific adverse events (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). </p> <p>Data from <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> (measured within 24 days of treatment) showed that there was no evidence of a difference between groups for nausea, vomiting and dizziness. Constipation was less frequent with morphine compared with hydromorphone (<a href="#CD011108-tbl-0007">Table 4</a>). </p> <p> <ul id="CD011108-list-0011"> <li> <p>Nausea (RR 0.94, 95% CI 0.66, 1.30; n = 200).</p> </li> <li> <p>Vomiting (RR 0.87, 95% CI 0.58, 1.31; n = 200).</p> </li> <li> <p>Dizziness (RR 1.15, 95% CI 0.71, 1.88; n = 200).</p> </li> <li> <p>Constipation (RR 1.56, 95% CI 1.12 to 2.17; n = 200).</p> </li> </ul> </p> <p>There were lower risks of confusion and diarrhoea in the morphine group once we had taken into account the missing data in a sensitivity analysis (see <a href="#CD011108-tbl-0007">Table 4</a>) (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>). However, for data based on completers only (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>), the results were different, see 'Sensitivity analysis for hydromorphone compared with morphine' below for further details. The type and number of other adverse events appeared to be balanced between groups in <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> without any obvious differences. See <a href="#CD011108-tbl-0007">Table 4</a> for a detailed account. </p> <p>Data from <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> (measured during the three‐month follow‐up) found no clear evidence of a difference between groups for common adverse events including drug dependence, respiratory depression, pump‐related problems, sensorimotor disorder, low intracranial pressure, cerebrospinal fluid leak, anorexia, catheter problems, dizziness, pruritus, vomiting, nausea, urinary retention, constipation and infections or pocket problems (P &gt; 0.05). Only numerical data for constipation were extractable (RR 0.65, 95% CI 0.42 to 1.00; P = 0.05; <a href="#CD011108-tbl-0007">Table 4</a>). </p> <p><a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> counted the number of adverse events that occurred within six days of treatment in each group (88 adverse events reported by 35 participants), therefore the data were not suitable for meta‐analysis. </p> <p>We rated the certainty of the evidence for specific adverse events as very low, downgrading twice for very serious study limitations and once for serious imprecision (<a href="./full#CD011108-tbl-0002">summary of findings Table 2</a>). We decided not to downgrade for publication bias as the outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </section> <section id="CD011108-sec-0082"> <h5 class="title">3.4 Serious adverse events</h5> <p>Only one study reported the incidence of serious adverse events. There was no clear evidence of a difference between groups (RR 1.02, 95% CI 0.48 to 2.16; P = 0.96; <a href="#CD011108-tbl-0007">Table 4</a>) (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>). We rated the certainty of the evidence for serious adverse events as very low, downgrading twice for very serious study limitations and once for serious imprecision. </p> </section> <section id="CD011108-sec-0083"> <h5 class="title">3.5 Quality of life</h5> <p>One study was predefined to report quality of life in the protocol, but reported no data or results in the full text (<a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). </p> </section> <section id="CD011108-sec-0084"> <h5 class="title">3.6 Leaving the study early</h5> <p>One study (200 participants) reported leaving the study early within 24 days of treatment (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>). There was no clear evidence of a difference between OROS hydromorphone and morphine sulphate (RR 1.42, 95% CI 0.95 to 2.12; <a href="#CD011108-tbl-0007">Table 4</a>). This study provided data for participants leaving the study early due to adverse events (15/99 with hydromorphone versus 11/101 with morphine) and lack of efficacy (11/99 with hydromorphone versus 4/101 with morphine), which also demonstrated no apparent difference. </p> <p>One study (233 participants) reported leaving the study early at the end of three‐month follow‐up (<a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). There was no clear evidence of a difference between hydromorphone and morphine (RR 0.97, 95% CI 0.89 to 1.05; P = 0.478; <a href="#CD011108-tbl-0007">Table 4</a>). This study provided data for participants leaving the study early due to discontinued intervention (25/121 with hydromorphone versus 26/112 with morphine), lost to follow‐up (8/121 with hydromorphone versus 9/112 with morphine), changed to other therapy (13/121 with hydromorphone versus 13/112 with morphine), serious adverse events (4/121 with hydromorphone versus 4/112 with morphine), and death of cancer during trial (58/121 with hydromorphone versus 51/112 with morphine). </p> <p>We rated the certainty of the evidence for leaving the study early as very low, downgrading twice for very serious study limitations and once for serious imprecision (<a href="./full#CD011108-tbl-0002">summary of findings Table 2</a>). We decided not to downgrade for publication bias as the outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </section> <section id="CD011108-sec-0085"> <h5 class="title">3.7 Death</h5> <p>One study (200 participants) reported death that occurred within 24 days of treatment (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>). There was no evidence of a difference between hydromorphone and morphine (RR 0.15, 95% CI 0.01 to 2.78; <a href="#CD011108-tbl-0007">Table 4</a>). </p> <p>Another study (233 participants) reported death which occurred within three‐month follow‐up (<a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). There was no evidence of a difference between hydromorphone and morphine (RR 1.05, 95% CI 0.80 to 1.39; P = 0.7143; <a href="#CD011108-tbl-0007">Table 4</a>). </p> <p>We rated the certainty of the evidence for death as very low, downgrading for very serious study limitations (high risk of bias of other bias, incomplete data and reporting bias) and imprecision. </p> </section> <section id="CD011108-sec-0086"> <h5 class="title">Sensitivity analysis for hydromorphone compared with morphine</h5> <p>In accordance with our protocol, we performed a sensitivity analysis for the adverse events data reported by <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> comparing the effect size with and without dropouts. When we included dropouts in the analysis, we found a clear difference favouring the morphine group for confusion (RR 1.74, 95% CI 1.02 to 2.96), constipation (RR 1.56, 95% CI 1.12 to 2.17) and diarrhoea (RR 1.74, 95% CI 1.02 to 2.96). However, when we analysed completers data, only constipation remained clearly different (RR 1.76, 95% CI 1.09 to 2.87). </p> </section> </section> <section id="CD011108-sec-0087"> <h4 class="title">Comparison 4: hydromorphone compared with fentanyl</h4> <p>One study compared hydromorphone with fentanyl (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>). </p> <section id="CD011108-sec-0088"> <h5 class="title">4.1 Participant‐reported pain intensity</h5> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> measured mean decreases of pain ratings (using an NRS) at 60 minutes after treatment initiation (<a href="#CD011108-tbl-0008">Table 5</a>). There was no evidence of a difference between hydromorphone and fentanyl in mean decrease from pain score at randomisation (MD –0.24, 95% CI –1.21 to 0.73; P = 0.63). In addition, there was no evidence of a difference in mean decrease from maximum pain score of 10 or from randomisation pain score between groups (MD 0.81, 95% CI –0.18 to 1.80; P = 0.11). </p> <div class="table" id="CD011108-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison 4: hydromorphone versus fentanyl (pain intensity: numerical rating scale pain scores)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Oxycodone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>MD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Pain ratings 60 minutes after treatment initiation (T0)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease from pain score at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.24 (−1.21 to 0.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease from maximum pain score of 10 for the IV hydromorphone group and from randomisation pain score for the IN fentanyl group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (−0.18 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; IN: intranasal; IV: intravenous; MD: mean difference; n: number; SD: standard deviation. </p> </div> </div> <p>We found no studies reporting the number of participants who achieved 'no worse than mild pain'. </p> <p>We rated the certainty of the evidence for participant‐reported pain intensity as very low, downgrading twice for very serious study limitations and once for serious imprecision (<a href="./full#CD011108-tbl-0003">summary of findings Table 3</a>). We decided not to downgrade for publication bias as the outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </section> <section id="CD011108-sec-0089"> <h5 class="title">4.2 Participant‐reported pain relief</h5> <p>The study did not report participant‐reported pain relief.</p> </section> <section id="CD011108-sec-0090"> <h5 class="title">4.3 Specific adverse events</h5> <p>The study did not report specific adverse events.</p> </section> <section id="CD011108-sec-0091"> <h5 class="title">4.4 Serious adverse events</h5> <p>The study did not report serious adverse events.</p> </section> <section id="CD011108-sec-0092"> <h5 class="title">4.5 Quality of life</h5> <p>The study did not report quality of life.</p> </section> <section id="CD011108-sec-0093"> <h5 class="title">4.6 Leaving the study early</h5> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> reported the number of participants leaving the study early during treatment. There was no evidence of a difference between groups (RR 5.00, 95% CI 0.24 to 101.11; P = 0.294; <a href="#CD011108-tbl-0009">Table 6</a>). The study provided data for participants leaving the study early due to withdrawn consent (1/42 with hydromorphone versus 0/42 with morphine) and ineligible due to abnormal electrocardiograph (1/42 with hydromorphone versus 0/42 with morphine). </p> <div class="table" id="CD011108-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison 4: hydromorphone versus fentanyl (leaving study early)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Morphine</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>RR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.00 (0.24 to 101.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrew consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 (0.13 to 71.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ineligible due to abnormal electrocardiogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 (0.13 to 71.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; n: number; RR: risk ratio.</p> </div> </div> <p>We rated the certainty of the evidence for leaving the study early as very low, downgrading twice for very serious study limitations and once for serious imprecision. </p> </section> <section id="CD011108-sec-0094"> <h5 class="title">4.7 Death</h5> <p>The study did not report death.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011108-sec-0095" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011108-sec-0095"></div> <section id="CD011108-sec-0096"> <h3 class="title" id="CD011108-sec-0096">Summary of main results</h3> <p>We included eight studies with 1283 participants in this review (data for 1181 participants available for analysis). Four studies compared hydromorphone with oxycodone, three studies compared hydromorphone with morphine and one study compared hydromorphone with fentanyl. Overall, the data demonstrated no clear evidence of a difference between groups for all comparisons; however, data were skewed, and we did not use meta‐analysis for primary outcomes. Participants achieved no worse than mild pain in all included studies (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>). For the safety of drugs, the risk of confusion, constipation and diarrhoea favoured the morphine group, and there was no clear evidence of a difference between groups for other specific adverse events (<a href="#CD011108-tbl-0005">Table 2</a>; <a href="#CD011108-tbl-0007">Table 4</a>). Regarding serious adverse events, there was no clear evidence of a difference between hydromorphone and oxycodone (<a href="./references#CD011108-fig-0006" title="">Analysis 1.3</a>), or hydromorphone and morphine (<a href="#CD011108-tbl-0007">Table 4</a>). The observed differences favouring morphine were questionable due to the instability of analysis caused by missing data from the trials. <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> reported three deaths in the morphine group during the trial period, but trialists claimed that they were not related to the drug but were the consequences of cancer. <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> and <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> also reported death (<a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>: eight in the hydromorphone group and 16 in the oxycodone group; <a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>: 58 in the hydromorphone group and 51 in the morphine group), but the most common reason was disease progression. <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> and <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> reported serious adverse events (including deaths), but no specific number of deaths in each group. The two studies that contributed the most data in this review had over 10% dropout rates, but the reasons and proportion of dropouts were balanced between groups (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>). </p> <p>Moreover, we are aware that results from this review may indicate the difference between different dosages of opioid rather than different opioids. However, this review was not able to convert included treatments' dosage into any equivalent dose to a particular drug, such as morphine, to confirm this issue is due to the treatment dosage in the included studies which were mostly reported as a mean rather than a range. It would be difficult to give a precise equivalent dose to morphine. Therefore, the current conclusion was given in relation to different drugs. </p> <p>In addition, opioid rotation is a common practice for the improvement of pain control or drug tolerability, or both (<a href="./references#CD011108-bbs2-0062" title="QuigleyC . Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews2004, Issue 3. Art. No: CD004847. [DOI: 10.1002/14651858.CD004847.pub2]">Quigley 2004</a>; <a href="./references#CD011108-bbs2-0067" title="SchusterM , BayerO , HeidF , Laufenberg-FeldmannR . Opioid Rotation in Cancer Pain Treatment: A Systematic Review.. Deutsches Ärzteblatt International2018;115(9):135.">Schuster 2018</a>). When these appropriate interventions have been exhausted or when adverse effects are rapid and severe (or both), rotation to an alternative opioid may help, but there is a lack of evidence to support rotation (<a href="./references#CD011108-bbs2-0067" title="SchusterM , BayerO , HeidF , Laufenberg-FeldmannR . Opioid Rotation in Cancer Pain Treatment: A Systematic Review.. Deutsches Ärzteblatt International2018;115(9):135.">Schuster 2018</a>). </p> </section> <section id="CD011108-sec-0097"> <h3 class="title" id="CD011108-sec-0097">Overall completeness and applicability of evidence</h3> <p>There is a lack of data on children and younger adults for the use of hydromorphone for cancer pain. The mean age of participants included in this review was approximately 61 years. None of the studies stated the cancer stage. We were able to collect data on the primary outcome of no worse than mild pain and most of the secondary outcomes that we intended to measure, with the exception of quality of life. Applicability of the evidence was limited as the included studies compared only oxycodone, morphine and fentanyl with hydromorphone. Included studies were conducted in high‐income countries, which may have limited generalisability in some lower‐income countries. </p> <p>There were no studies comparing hydromorphone with placebo. We found no published trials that compared hydromorphone with placebo regarding effectiveness and safety. It is very interesting since 'a randomised placebo‐controlled' clinical trial is agreed as the 'gold standard' for testing efficacy and safety in people. It might be explained that current international guidelines suggest opioids dose equivalence to morphine, which might slightly encourage researchers to compare opioids with morphine. In addition, there are ethical issues with placebo controls in people with cancer pain. The current evidence included comparisons between hydromorphone and morphine, fentanyl and oxycodone, which may reflect its effectiveness and safety. Although the included studies in this review did not identify any placebo‐controlled RCTs, we did identify an ongoing registered trial that is planning to compare hydromorphone with placebo. </p> <p>There was heterogeneity within the included trials with respect to their study designs, formulations used and durations of follow‐up. Two studies were cross‐over design and two used a parallel design using two phases. All studies used CR or ER opioids, yet one study included an initial phase which used an IR formulation (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>). The duration of follow‐up between the trials ranged from five to 28 days. These factors increased the difficulty of drawing specific conclusions from the studies. </p> <p>It is worth noting that two of the trials in this review used the OROS formulation of hydromorphone, which has some unique properties that differ from other formulations of hydromorphone (<a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>, n = 200; <a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a>, n = 260). It is a unique long‐acting opioid formulation that utilises Push‐Pull active osmotic technology and maintains consistent hydromorphone plasma concentrations throughout the 24‐hour dosing interval, providing long‐lasting analgesia (<a href="./references#CD011108-bbs2-0028" title="AngstMS , DroverDR , LotschJ , RamaswamyB , NaiduS , WadaDR , et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology2001;94(1):63-73. [PMID: 11135723]">Angst 2001</a>; <a href="./references#CD011108-bbs2-0034" title="DroverDR , AngstMS , ValleM , RamaswamyB , NaiduS , StanskiDR , et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology2002;97(4):827-36. [PMID: 12357147]">Drover 2002</a>; <a href="./references#CD011108-bbs2-0057" title="PalangioM , NorthfeltDW , PortenoyRK , BrookoffD , Doyle RT Jr, DornseifBE , et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. Journal of Pain and Symptom Management2002;23(5):355-68. [PMID: 12007754]">Palangio 2002</a>). The dosage form controls the drug release into the body, almost independently from factors such as the surrounding pH or gastric motility (<a href="./references#CD011108-bbs2-0029" title="BassDM , PrevoM , WaxmanDS . Gastrointestinal safety of an extended-release, nondeformable, oral dosage form (OROS): a retrospective study. Drug Safety2002;25(14):1021-33. [PMID: 12408733]">Bass 2002</a>; <a href="./references#CD011108-bbs2-0072" title="VermaRK , KrishnaDM , GargS . Formulation aspects in the development of osmotically controlled oral drug delivery systems. Journal of Controlled Release2002;79(1-3):7-27. [PMID: 11853915]">Verma 2002</a>). There is a minimal effect of food on the rate and extent of absorption of hydromorphone from OROS hydromorphone (<a href="./references#CD011108-bbs2-0066" title="SathyanG , XuE , ThipphawongJ , GuptaSK . Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clinical Pharmacology2007;7:2. [PMID: 17270055]">Sathyan 2007</a>). It has been reported that the pharmacokinetics of OROS hydromorphone are also minimally affected by alcohol. These unique features of OROS may further limit the generalisability of evidence. Similarly, we are aware of other formulations of hydromorphone (and other opioids), such as immediate release and sustained release formulation, which may have potential benefits for specific groups of people with cancer, but we found no evidence for these as part of this review. </p> <p>Noteworthy, none of the eight included studies reported participants' quality of life. One study planned to measure quality of life in the protocol, but no outcomes were identified in the published report. It is clear that people with cancer who experience pain may face some psychological problems, social adverse effects, and eventually, a poor quality of life. Therefore, the absence of quality of life evidence may indicate a research gap in people with cancer pain. </p> </section> <section id="CD011108-sec-0098"> <h3 class="title" id="CD011108-sec-0098">Quality of the evidence</h3> <p>We judged all eight studies at high risk of bias overall because they all had at least one domain with high risk of bias. </p> <p>The two most prominent risks of bias concerned sample size and sponsorship. One of the studies only had 44 participants (<a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>), and six studies were either funded or conducted by industry (<a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a>; <a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a>; <a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a>; <a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a>; <a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a>; <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>). One study was at high risk overall due to selective reporting and high attrition rate (<a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a>). The certainty of the body of evidence was very low, mainly due to the high risk of bias judged due to pharmaceutical company sponsorship and potential conflict of interest, as well as imprecision around effect estimates. Although the certainty may be downgraded also for inconsistency and publication bias, no further actions were taked since the the outcomes had already been downgraded three times for other factors. High attrition rate also played a role in downgrading the overall certainty of the evidence. See <a href="./full#CD011108-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD011108-tbl-0002">summary of findings Table 2</a>; and <a href="./full#CD011108-tbl-0003">summary of findings Table 3</a> for detailed assessment results of each individual outcome. The current body of evidence identified does not allow a robust conclusion, as most data for the outcomes were either skewed or had wide CIs around the estimated effect size. </p> </section> <section id="CD011108-sec-0099"> <h3 class="title" id="CD011108-sec-0099">Potential biases in the review process</h3> <p>Although we searched mainstream biomedical databases and clinical trials registries, searches beyond these resources to include other non‐English literature may improve the comprehensiveness of the search results. Two review authors independently performed screening and data extraction, but we were unable to extract any numerical data from <a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a>, which may have had some influence on the results. </p> </section> <section id="CD011108-sec-0100"> <h3 class="title" id="CD011108-sec-0100">Agreements and disagreements with other studies or reviews</h3> <p>The current review indicated little difference between hydromorphone and three other opioids, oxycodone, morphine and fentanyl, in terms of analgesic efficacy. This finding is consistent with the 2012 European Association for Palliative Care (EAPC) guidelines (<a href="./references#CD011108-bbs2-0032" title="CaraceniA , HanksG , KaasaS , BennettMI , BrunelliC , ChernyN , et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology2012;13(2):e58-68.">Caraceni 2012</a>), which included a series of systematic reviews of the evidence for opioids in people with moderate to severe cancer pain (<a href="./references#CD011108-bbs2-0031" title="CaraceniA , PigniA , BrunelliC . Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliative Medicine2011;25(5):402-9.">Caraceni 2011</a>; <a href="./references#CD011108-bbs2-0046" title="KingS , ForbesK , HanksGW , FerroCJ , ChambersEJ . A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative Medicine2011;25(5):525-52.">King 2011a</a>; <a href="./references#CD011108-bbs2-0047" title="KingSJ , ReidC , ForbesK , HanksG . A systematic review of oxycodone in the management of cancer pain. Palliative Medicine2011;25(5):454-70. [PMID: 21708852]">King 2011b</a>; <a href="./references#CD011108-bbs2-0058" title="PigniA , BrunelliC , CaraceniA . The role of hydromorphone in cancer pain treatment: a systematic review. Palliative Medicine2011;25(5):471-7.">Pigni 2011</a>). The reviews concluded that there is a lack of evidence to demonstrate superiority or inferiority of hydromorphone in comparison with other analgesics and EAPC made a weak recommendation that hydromorphone, morphine, oxycodone or fentanyl could be used as the first choice for step three of the WHO analgesic ladder. <a href="./references#CD011108-bbs2-0077" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592.pub2]">Wiffen 2017a</a> conducted an overview of reviews investigating the effect of opioids for cancer pain. The study also found that the amount and quality of evidence on using opioids for the treatment of cancer pain is generally very low, and current evidence provides little information on whether there are any differences in effectiveness and adverse events between different types of opioids. The study also concluded that most people will experience adverse events after taking opioids, and the more common adverse events are constipation and nausea (<a href="./references#CD011108-bbs2-0077" title="WiffenPJ , WeeB , DerryS , BellRF , MooreRA . Opioids for cancer pain – an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012592. [DOI: 10.1002/14651858.CD012592.pub2]">Wiffen 2017a</a>). The proportion of people experiencing intolerable adverse events is around 1/10 or 2/10, which may lead to a change in treatment. In our review, the most common specific adverse events of hydromorphone were also constipation (52/99 participants) and nausea (37/99 participants). The risks of specific adverse events higher than 20% were constipation (53%), nausea (37%), somnolence (30%), confusion (29%), diarrhoea (29%), vomiting (29%), asthenia (28%), anxiety (27%), insomnia (27%), dizziness (26%), fatigue (26%), pyrexia (26%), anaemia (25%), headache (25%), pruritus (25%), anorexia (24%) and peripheral oedema (23%). The incidence of serious adverse events of hydromorphone was around 8% to 12%. </p> <p>The results of this review do not differ from the results of the previous Cochrane Review (<a href="./references#CD011108-bbs2-0081" title="BaoYJ , HouW , KongXY , YangL , XiaJ , HuaBJ , KnaggsR . Hydromorphone for cancer pain. Cochrane Database of Systematic Reviews2016;CD01110(10):DOI: 10.1002/14651858.CD011108.pub2.">Bao 2016</a>; <a href="./references#CD011108-bbs2-0061" title="QuigleyC , WiffenP . A systematic review of hydromorphone in acute and chronic pain. Journal of Pain and Symptom Management2003;25(2):169-78. [PMID: 12590032]">Quigley 2003</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011108-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/urn:x-wiley:14651858:media:CD011108:CD011108-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (update)." data-id="CD011108-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_t/tCD011108-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (update).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011108-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/urn:x-wiley:14651858:media:CD011108:CD011108-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011108-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_t/tCD011108-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011108-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/urn:x-wiley:14651858:media:CD011108:CD011108-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011108-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_t/tCD011108-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011108-fig-0004"> <p> <div class="table" id="CD011108-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>Participant‐reported pain intensity (skewed data)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Standard deviation</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Visual analogue scale (VAS) endpoint pain intensity score (high score = poor outcome)</b> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Hagen 1997</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydromorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Inoue 2017</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydromorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Inoue 2018</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hydromorphone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oxycodone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Hydromorphone versus oxycodone, Outcome 1: Participant‐reported pain intensity (skewed data) </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#CD011108-fig-0004">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011108-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/urn:x-wiley:14651858:media:CD011108:CD011108-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydromorphone versus oxycodone, Outcome 2: Specific adverse events" data-id="CD011108-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_t/tCD011108-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Hydromorphone versus oxycodone, Outcome 2: Specific adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#CD011108-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011108-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/urn:x-wiley:14651858:media:CD011108:CD011108-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydromorphone versus oxycodone, Outcome 3: Serious adverse events" data-id="CD011108-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_t/tCD011108-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Hydromorphone versus oxycodone, Outcome 3: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#CD011108-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011108-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/urn:x-wiley:14651858:media:CD011108:CD011108-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Hydromorphone versus oxycodone, Outcome 4: Leaving the study early" data-id="CD011108-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_t/tCD011108-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Hydromorphone versus oxycodone, Outcome 4: Leaving the study early</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#CD011108-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/media/CDSR/CD011108/image_n/nCD011108-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011108-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hydromorphone compared with oxycodone for people with moderate to severe cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hydromorphone compared with oxycodone for people with moderate to severe cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with moderate to severe cancer pain </p> <p><b>Setting:</b> unclear, not specified in included studies </p> <p><b>Intervention:</b> hydromorphone </p> <p><b>Comparison:</b> oxycodone </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with oxycodone</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hydromorphone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain intensity</b> (as measured by VAS or BPI) </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>For pain intensity, the results were similar in hydromorphone and oxycodone groups, although data were skewed. Only 1 study showed mean pain levels of 'no worse than mild pain' for oxycodone and hydromorphone groups. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>462<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain intensity scores: 3 studies (n = 381) using VAS (0–100, higher = worse outcome): mean endpoint score for hydromorphone in each study was 28.86 (SD 17.08, n = 19); 23 (SD 17.91, n = 86); 24.7 (SD 22.1, n = 88). Mean endpoint score for oxycodone in each study was 30.30 (SD 25.33, n = 12); 23.2 (SD 18.83, n = 92); 27.9 (SD 21.05, n = 84). 1 study using BPI (0–10; higher = worse outcome): mean change score of 'pain at its worst in the past 24 hours' for hydromorphone −1.8 (SD 3.29, n = 81). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – nausea</b> </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.13</b><br/>(0.74 to 1.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>288 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>326 per 1000<br/>(213 to 499) more </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>237 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>267 per 1000<br/>(175 to 409) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – vomiting</b> </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.18</b><br/>(0.72 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>333 per 1000<br/>(203 to 547) more </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>265 per 1000<br/>(162 to 436) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – dizziness</b> </p> <p>Follow‐up: 7–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.91</b><br/>(0.58 to 1.44) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>441<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>143 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>131 per 1000<br/>(83 to 207) fewer </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>132 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>120 per 1000<br/>(77 to 191) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Specific adverse events – constipation</b> </p> <p>Follow‐up: 5–28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.92</b><br/>(0.72 to 1.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>622<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>282 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>259 per 1000<br/>(203 to 336) fewer </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>248 per 1000<br/>(194 to 321) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BPI:</b> Brief Pain Inventory; <b>CI:</b> confidence interval; <b>n:</b> number of participants; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to very serious study limitations: studies were rated at high risk of bias overall, mainly accounted for by attrition bias and funding bias.<br/><sup>b</sup>Downgraded once due to serious imprecision: all studies had fewer than 200 participants in each treatment arm. Also sample size was smaller than optimal information size (GRADE guidelines 6, <a href="./references#CD011108-bbs2-0039" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>); CIs around estimate of effect were wide and included null effect and appreciable benefit/harm.<br/><sup>c</sup>Decision taken not to downgrade due to publication bias: although publication bias was highly suspected due to the small number of trials identified, this outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate.<br/><sup>d</sup>Decision taken not to downgrade due to inconsistency: although inconsistency was highly suspected due to I<sup>2</sup> value greater than 50% with unexplainable heterogeneity, this outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Hydromorphone compared with oxycodone for people with moderate to severe cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011108-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hydromorphone compared with morphine for people with moderate to severe cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Hydromorphone compared with morphine for people with moderate to severe cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with moderate to severe cancer pain </p> <p><b>Setting:</b> inpatients, outpatients and day patients </p> <p><b>Intervention:</b> hydromorphone </p> <p><b>Comparison:</b> morphine </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with morphine</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with hydromorphone</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain intensity</b> (as measured by BPI and VAS) </p> <p>Follow‐up: 12 weeks</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>For pain intensity measured by BPI at 24 days, the results showed slightly higher mean endpoint scores for 'worst pain' in morphine group and similar mean scores for 'average' and 'least' pain in hydromorphone and morphine groups. For pain intensity measured by VAS from weeks 1–12, both morphine and hydromorphone groups had mean pain levels of 'no worse than mild pain.' Evidence of hydromorphone vs morphine on pain intensity was very uncertain. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 study (n = 200) using subscale data derived from BPI scale (0–10; higher = worse outcome): mean endpoint score for 'worst pain:' hydromorphone 3.5 (SD 2.9, n = 99); morphine 4.3 (SD 3.0, n = 101). Mean scores on 'least pain' and 'average pain' were almost identical. 1 study (n = 233) using VAS scale (0–10; higher = worse outcome) measured pain intensity from week 1 to week 12 of treatment. Both groups had identical scores at all the measured timepoints (P &gt; 0.05). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Participant‐reported pain relief</b> </p> <p>Follow‐up: mean 12 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b><br/>(0.84 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>233<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>705 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>698 per 1000<br/>(593 to 832) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific adverse events – nausea</b> </p> <p>Follow‐up: 24 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.94</b><br/>(0.66 to 1.30) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>396 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>372 per 1000<br/>(261 to 515) fewer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific adverse events – vomiting</b> </p> <p>Follow‐up: 24 days</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.87</b><br/>(0.58 to 1.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>337 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>293 per 1000<br/>(195 to 441) fewer </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Specific adverse events – dizziness</b><br/>Follow‐up: 24 days </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.15</b><br/>(0.71 to 1.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>228 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000<br/>(162 to 428) more </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – constipation</b><br/>Follow‐up: 24 days to 12 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The higher incidence of constipation of hydromorphone occurred at a shorter treatment point (at 24 days of treatment), but not a longer treatment point (12 weeks). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>433<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported the incidence of constipation at different timepoints. 1 study (n = 200) measured at 24 days of treatment found a significantly higher incidence of constipation with hydromorphone than with morphine (RR 1.56, 95% CI 1.12 to 2.17; P = 0.009). 1 study (n = 233) measured at 12 weeks' follow‐up found no clear difference between 2 groups (RR 0.65, 95% CI 0.42 to 1.00; P = 0.055). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>BPI:</b> Brief Pain Inventory; <b>CI:</b> confidence interval; <b>n:</b> number of participants; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SD:</b> standard deviation; <b>VAS:</b> visual analogue scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to very serious study limitations: all studies were rated at high risk of bias for at least two domains.<br/><sup>b</sup>Downgraded once due to serious imprecision: studies contained fewer than 200 participants in each treatment arm, and sample size was smaller than optimal information size (<a href="./references#CD011108-bbs2-0039" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">Guyatt 2011</a>); CI around estimate of effect was wide and included no effect and appreciable benefit/harm.<br/><sup>c</sup>Decision made not to downgrade due to publication bias: although publication bias was highly suspected due to the small number of trials identified, this outcome had already been downgraded three times for other factors, therefore, further downgrading would be inappropriate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Hydromorphone compared with morphine for people with moderate to severe cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011108-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hydromorphone compared with fentanyl for people with moderate to severe cancer pain</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Hydromorphone compared with fentanyl for people with moderate to severe cancer pain</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with moderate to severe cancer pain </p> <p><b>Setting:</b> included studies did not specify inpatients, outpatients or community settings </p> <p><b>Intervention:</b> hydromorphone </p> <p><b>Comparison:</b> fentanyl </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Impact</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain intensity</b> (as measured by NRS)<br/>Follow‐up: mean 1 day </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 study (n = 82) measured pain intensity using NRS at 60 minutes after treatment initiation. The mean decrease from pain score at randomisation showed no clear difference between the 2 groups (MD −0.24, 95% CI −1.21 to 0.73; P = 0.63). In addition, the mean decrease from maximum pain score of 10 for the hydromorphone group and from randomisation pain score for the fentanyl group showed no clear difference (MD 0.81, 95% CI −0.18 to 1.80; P = 0.11). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,b,c</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported pain relief</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – nausea</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – vomiting</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – dizziness</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Specific adverse events – constipation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Not reported.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>n:</b> number of participants; <b>MD:</b> mean difference; <b>NRS:</b> numerical rating scale; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice due to very serious study limitations: study was rated at high risk of bias for at least two domains.<br/><sup>b</sup>Downgraded once due to serious imprecision: CIs around estimate of effect were wide and included null effect and appreciable benefit/harm.<br/><sup>c</sup>Decision made not to downgrade due to publication bias: although publication bias was highly suspected due to the small number of trials identified, this outcome had already been downgraded three times by other factors, therefore further downgrade would be inappropriate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Hydromorphone compared with fentanyl for people with moderate to severe cancer pain</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011108-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison 2: hydromorphone versus oxycodone (pain intensity and adverse events from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Oxycodone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Difference</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>MD (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Categorical pain intensity (ordinal scale) – at 7 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.10 (−0.15 to 0.35)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPI (changed data) – at 28 days of maintenance therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−1.7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.10 (−1.67 to 1.47)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific adverse events – nausea – at 7 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−0.63 (−15.13 to 13.87)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Specific adverse events – sedation – at 7 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>−4.89 (−22.15 to 12.37)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0002" title="HagenNA , BabulN . Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer1997;79(7):1428-37. ">Hagen 1997</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>BPI: Brief Pain Inventory; CI: confidence interval; MD: mean difference; n: number of participants; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison 2: hydromorphone versus oxycodone (pain intensity and adverse events from single study data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011108-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparison 2: hydromorphone versus oxycodone (adverse events and deaths from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Oxycodone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>RR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>RR</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Specific adverse events</b> – end of treatment (<b>ranged from 5 days of treatment to 28 days</b> <b>of maintenance therapy)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.21 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal distension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82 (0.35 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.89 (0.47 to 1.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.48 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bone marrow failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.85 (0.39 to 1.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10 (0.48 to 2.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delirium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.58 (0.22 to 1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0005" title="InoueS , SaitoY , TsunetoS , ArugaE , TakahashiH , UemoriM . A randomised, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients. Japanese Journal of Clinical Oncology2018;48(6):542-7. ">Inoue 2018</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.23 (0.43 to 3.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperhidrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.42 (0.15 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Malaise</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45 (0.12 to 1.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0004" title="InoueS , SaitoY , TsunetoS , ArugaE , IdeA , KakuraiY . A randomised, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain relief). Journal of Pain Research2017;10:1953-62. ">Inoue 2017</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neutrophil count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00 (0.41 to 2.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oedema peripheral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.30 (0.59 to 2.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Platelet count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.40 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.84 (0.53 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13 (0.45 to 2.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 (0.21 to 1.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>White blood cell count decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.71 (0.39 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Death</b> – at 28 days of maintenance therapy </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 (0.22 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011108-bbs2-0008" title="NCT01205126. An efficacy and safety study of oral osmotic therapeutic system (OROS) hydromorphone hydrochloride (HCl) in participants with cancer related pain [A randomized, double-blind, active controlled, multi-center study to investigate the safety and efficacy of OROS hydromorphone HCl once-daily compared with oxycodone HCL controlled-release twice daily in subjects with cancer pain]. clinicaltrials.gov/ct2/show/NCT01205126 (first received 5 August 2010). YuS , ShenW , YuL , HouY , HanJ , RichardsHM . Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. Journal of Pain2014;15(8):835-44. [PMID: 24846822]">Yu 2014</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; n: number; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparison 2: hydromorphone versus oxycodone (adverse events and deaths from single study data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011108-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Comparison 3: hydromorphone versus morphine (participant‐reported pain intensity: Brief Pain Inventory endpoint and visual analogue scale score from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Morphine</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>MD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>MD</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>BPI – worst pain subscale score at 24 days of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.80 (−1.62 to 0.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>BPI – least pain subscale score at 24 days of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00 (−0.55 to 0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>BPI – mean pain at 24 days of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.20 (−0.63 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.64</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 1 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.22 (−0.15 to 0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="12" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 2 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (−0.36 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 3 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.14 (−0.47 to 0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.39</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 4 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.04 (−0.35 to 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.80</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 5 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.23 (−0.54 to 0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 6 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.16 (−0.48 to 0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.35</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 7 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.02 (−0.32 to 0.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 8 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.06 (−0.25 to 0.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.69</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 9 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.02 (−0.32 to 0.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 10 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.14 (−0.17 to 0.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.38</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 11 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.04 (−0.34 to 0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.82</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>VAS</b> –<b>at week 12 of treatment</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.15 (−0.45 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.34</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>BPI: Brief Pain Inventory; CI: confidence interval; MD: mean difference; n: number of participants; SD: standard deviation; VAS: visual analogue scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Comparison 3: hydromorphone versus morphine (participant‐reported pain intensity: Brief Pain Inventory endpoint and visual analogue scale score from single study data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011108-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison 3: hydromorphone versus morphine (pain relief rate 50% or greater, adverse events, leaving study early and death from single study data)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Morphine</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>RR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Participants improved at 84 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>% of participants with pain relief rate ≥ 50%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00 (0.84 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.962</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Specific adverse event</b> –<b>measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (0.73 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="17" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.22 (0.72 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.72 (0.99 to 2.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.90 to 2.51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (1.12 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.009<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.74 (1.02 to 2.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.15 (0.71 to 1.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.74 (1.02 to 2.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.26 (0.76 to 2.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.50 (0.87 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45 (0.86 to 2.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (0.66 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oedema peripheral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.61 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pruritus</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.28 (0.76 to 2.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (0.90 to 2.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.13 (0.73 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87 (0.58 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Serious adverse event</b> –<b>measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.48 to 2.16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Adverse event measured during 84 days follow‐up of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65 (0.42 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Leaving study early measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42 (0.95 to 2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.39 (0.67 to 2.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.81 (0.92 to 8.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Leaving study early measured at 84 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.89 to 1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89 (0.55 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to lost to follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.33 to 2.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to change to other therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.45 to 1.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Due to serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.24 to 3.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Death measured at 84 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.80 to 1.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0006" title="ISRCTN17751043. The efficacy, safety and cost-effectiveness analysis of morphine and hydromorphone in intrathecal drug deliver system for intractable cancer pain. https://trialsearch.who.int/Trial2.aspx?TrialID=ISRCTN17751043 (Date of registration 26 January 2016). MaK , JinY , WangL , FengZY , SongT , YangXQ , et al. Intrathecal delivery of hydromorphone vs morphine for refractory cancer pain: a multicenter, randomized, single-blind, controlled noninferiority trial. Pain2020;161(11):2502-10. ">Ma 2020</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Death measured at 24 days of treatment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15 (0.01 to 2.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011108-bbs2-0003" title="HannaM , ThipphawongJ , 118 Study Group. A randomized, double-blind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliative Care2008;7:17. NCT00410540. A study of OROS hydromorphone HCl vs morphine in cancer pain patients [A randomized, double-blind, controlled trial of hydromorphone (immediate and sustained- release) vs morphine (immediate and sustained-release) in cancer pain]. clinicaltrials.gov/ct2/show/NCT00410540 (first received: 12 December 2006). ">Hanna 2008</a> </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Adverse events‐treatment related occurred within 6 days of treatment</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Counts of reported events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Treatment related</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Counts of reported events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Treatment related</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>—</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study ID</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal discomfort/pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="10" valign="top"> <p><a href="./references#CD011108-bbs2-0007" title="MoriartyM , McDonaldCJ , MillerAJ . A randomised crossover comparison of controlled release hydromorphone tablets with controlled release morphine tablets in patients with cancer pain. Journal of Clinical Research1999;2:1-8. ">Moriarty 1999</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TOTAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Statistically significant P value. </p> <p>CI: confidence interval; n: number; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Comparison 3: hydromorphone versus morphine (pain relief rate 50% or greater, adverse events, leaving study early and death from single study data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011108-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison 4: hydromorphone versus fentanyl (pain intensity: numerical rating scale pain scores)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign=""> <p><b>Oxycodone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>MD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mean</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SD</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>MD</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Pain ratings 60 minutes after treatment initiation (T0)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease from pain score at randomisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>−0.24 (−1.21 to 0.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease from maximum pain score of 10 for the IV hydromorphone group and from randomisation pain score for the IN fentanyl group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81 (−0.18 to 1.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.11</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>CI: confidence interval; IN: intranasal; IV: intravenous; MD: mean difference; n: number; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Comparison 4: hydromorphone versus fentanyl (pain intensity: numerical rating scale pain scores)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011108-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison 4: hydromorphone versus fentanyl (leaving study early)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Hydromorphone</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>Morphine</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="middle"> <p><b>RR</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>n participants with events</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Total n</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR</b> (<b>95% CI</b>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.00 (0.24 to 101.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD011108-bbs2-0001" title="BanalaSR , KhattabOK , PageVD , WarnekeCL , ToddKH , YeungSC . Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PloS One2020;15(7):e0235461. ">Banala 2020</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrew consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 (0.13 to 71.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ineligible due to abnormal electrocardiogram</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.00 (0.13 to 71.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI: confidence interval; n: number; RR: risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Comparison 4: hydromorphone versus fentanyl (leaving study early)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/full#CD011108-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011108-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hydromorphone versus oxycodone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participant‐reported pain intensity (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Visual analogue scale (VAS) endpoint pain intensity score (high score = poor outcome) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.79, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.74, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.72, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.58, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.5 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.6 Appetite loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.56, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.7 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.71, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>606</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.39, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>666</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.44, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Hydromorphone versus oxycodone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011108.pub3/references#CD011108-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011108.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011108-note-0013">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011108-note-0020">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011108-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011108-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD011108-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011108-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011108-note-0018">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011108-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011108-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011108\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011108\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011108\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011108\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011108\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011108.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011108.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011108.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011108.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011108.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718235488"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011108.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718235492"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011108.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcb61aedcf3fd',t:'MTc0MDcxODIzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 